

Authors	Publication title	Date	Journal	Funding acknowledgement	Competing interests	If relevant: clinical trial ID	Comments	Date of data extraction	
Afobi MO	Safety and immunogenicity of ChAd63 and MVA-ME-TRAP in West African Children and Infants	2016	Official journal of the American Society of Gene & Cell Therapy	Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVMC), a four and a half year integrated project funded by the European and Developing Countries Clinical Trials Partnership (EDCTP, grant number: IP 2008.31300.003). The work was also supported by the UK National Institute of Health Research (NIHR) through the NIHR Oxford Biomedical Research Centre ( <a href="http://www.oxfordorc.org/">http://www.oxfordorc.org/</a> ) (A91301 Adult Vaccine), The Wellcome Trust ( <a href="http://www.wellcome.ac.uk/">http://www.wellcome.ac.uk/</a> ) (084113/2/07/2) and the Medical Research Council. Co-funding was also provided by the Swedish International Development Cooperation Agency (Sida) and Irish Aid. This research was supported by the UK Medical Research Council (MRC) and the UK Department of Health (Department of Health) under the MRC/DfID Concordat agreement and MC_UP_A900/1122	AVSH is a named inventor on patent applications on malaria vectored vaccines and immunization regimens. Authors from NetHERa are employees of and/or shareholders in NetHERa, which is developing vectored vaccines for malaria and other diseases.	NCT01373879, NCT01450293, NCT01035647, PACTR1201204000362870, PACTR201401200263170, PACTR201208000404131	N/A	08/12/2020	
Alcock R	Long term thermostabilization of live poxviral and adenoviral vaccine vectors at supra-physiological temperatures in carbohydrate glass	2010	Elsevier - Vaccine	No funding disclosure found	Conflict of interest: SCG is a co-founder of, consultant to and shareholder in Vac-ctech plc which is developing vectored influenza and MERSvaccines.	N/A	No funding disclosure found	16/12/20	
Alharbi NK Alharbi NK	ChAdOx1 and MVA-based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice	2017	Vaccine	No funding statement found	SCG is a co-founder of, consultant to and shareholder in Vaccitech plc which is developing vectored influenza and MERS vaccines.	N/A	N/A	21/12/2020	
Alves E	Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels	2019	Nature	This study is funded by KAIMRC, project RC16/093 granted to the PI: Naif Khalaf Alharbi; in addition, animals, research farm, and animal logistics were financially supported by MEWA, Saudi Arabia. SCG is a Jenner Investigator and supported the manufacturing of the vaccine batch.	SCG is a co-founder of and consultant to Vaccitech, a spin-out company from the University of Oxford which has commercial rights to ChAdOx1 MERS. ChAdOx1 MERS vaccine is registered as an IP, number: WO 2018/215796. The remaining authors declare no potential conflict of interest.	N/A	N/A	18/12/20	
Alves E	Evaluation of Plasmodium vivax Cell-Traversing Protein for Dikinetes and Sporozoites as a Pre-replicative P. vivax Vaccine	2017	Clinical and Vaccine Immunology	The work was funded by a Wellcome Trust Career Development Fellowship award/grant number 097395/Z/11/Z to A.R.-S.	N/A	N/A	N/A	08/12/2020	
Antrozhus RD Asthagiri Arunankumar G	Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens	2014	Molecular Therapy	The study was funded by grants from the UK MRC, the NIHR through the Oxford Biomedical Research Centre, and the Oxford Martin School.	T.L is an Oxford Martin fellow. S.C.G and A.V.S.H. are Jenner Investigators. S.C.G, M.D.D. and A.V.S.H are named inventors on a patent application describing the ChAdOx1 vector (GB Patent Application No. 11088979.6).	NCT01623518	N/A	08/12/2020	
	Vaccination with viral vectors expressing NP, M2 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice	2019	Elsevier Vaccine	The study was funded by an MRC Biomedical Catalyst DPFS_DCS award (MR/N006372/1) in addition, this study was partially funded by the NIHR Centre of Excellence for Influenza Research and Surveillance contract/CEIRS, HHSN27201400008C. Andrian loannou was supported by an NIHR T32 Virus-Host Interactions training grant/ST32A007647-17).	The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccine with Florian Kammer being an inventor. Sarah Gilbert is an inventor on patents covering ChAdOx1 and MVA-NP-M2, filed and owned by the University of Oxford, and is a co-founder of and consultant to Vaccitech, a University of Oxford spin-out company which is undertaking advanced clinical development of viral vectored influenza vaccines.	N/A	N/A	18/12/20	
	Taloring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP-Virus-Like Particle and TRAP Viral Vectors	2018	Infection and Immunity	The work was funded by a Wellcome Trust Career Development Fellowship award/grant 097395/Z/11/Z to A.R.-S., who is also a Jenner Investigator and an Oxford Martin Fellow and is supported by MRC DPFS grant MR/N030878/1. A.M.S. was funded by VIMAR's program funding (P97/2007-2013) under grant agreement number 242095. E.A. was funded by CARES from Science without Border program. A.V.S.H. is supported by a Wellcome Trust grant (number 095540/Z/11/Z) and is a Jenner Investigator and an Oxford Martin Fellow.	N/A	N/A	N/A	10/12/2020	
Atcheson E	Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man	2012	Science Translational Medicine	European Union (Framework VI:HEPA/CAVAC); Medical Research Council (UK); Wellcome Trust; Oxford NIHR Biomedical Research Centre; James Martin School for 21st Century, Oxford; Wellcome Trust Clinical Research Facility, Birmingham; National Institute for Health and Research Liver Biomedical Research Unit, Birmingham; and NIH grant 1U19AI082830-01.	S. Colocca, A.F., R.C., and A.N. are named inventors on patent applications covering MCV vectored vaccines and chimpanzee ad-enovirus vectors [WO 2006133911 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093 (A3) chimpanzee adenovirus vaccine carriers, WO 03031588 (A2) hepatitis C virus vaccine], P.K. has acted as a consultant to Tibotec and Pfizer on antiviral therapy. Authors from Okairo are employees of and/or shareholders in Okairo. The other authors declare that they have no competing interests.	NCT01070407, 2007-004259-12	N/A	10/12/2020	
Barnes E Barnes E	ChAdOx1-HB1 therapeutic vaccine: Phase 1 study results in healthy volunteers and patients with chronic hepatitis B	2020	N/A - only on clinicaltrials.gov ( <a href="https://clinicaltrials.gov/ct2/show/NCT04297917">https://clinicaltrials.gov/ct2/show/NCT04297917</a> )	N/A	N/A	NCT04297917	Study still recruiting	18/12/20	
	Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites	2014	Infection and Immunity	The work was funded by a Wellcome Trust Career Development Fellowship award, grant number 097395, to A.R.S., A.R.-S. and A.V.S.H. are Jenner Investigators and Oxford Martin School Fellows. E.T.L. and T.M. are funded by the Medical Research Council and Cancer Research UK. Work at the Wellcome Trust Sanger Institute was funded by Wellcome Trust grant number W1098051.	N/A	N/A	N/A	10/12/2020	
Bauza K	Optimising immunogenicity with viral vectors: mixing MVA and MVA-S expressing the mycobacterial antigen Ag85A in a single injection	2012	Plos One	Funding was provided by NEW78VAC (EC FP7). HM is a Wellcome Trust Senior Research Fellow ( <a href="http://www.wellcome.ac.uk/">http://www.wellcome.ac.uk/</a> ; W1076943MA). HM, AH and AR-S are Jenner Institute Investigators. AR-S is a Wellcome Trust Career Development Fellow (097395). This work was supported by the UK Medical Research Council (MRC; <a href="http://www.mrc.ac.uk/">http://www.mrc.ac.uk/</a> ) [grant number G0700735]; the EMVDA (European Malaria Vaccine Development Association); <a href="http://www.emvda.org/">http://www.emvda.org/</a> ; a European Commission FP6-funded consortium (LSMR-CT-2002-037506); the UK National Institute of Health Research through the Oxford Biomedical Research Centre ( <a href="http://084113/2/07/2/">http://084113/2/07/2/</a> ); and by EVIMAR (http://www.evimar.org) funded by the European Community Seventh Framework Programme (FP7/2007-2013) [grant agreement No. 242095]. The G1A work was supported by the PATH Malaria Vaccine Initiative ( <a href="http://www.malaria-vaccine.org/">http://www.malaria-vaccine.org/</a> ) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases ( <a href="http://www.niaid.nih.gov/">http://www.niaid.nih.gov/</a> ). SHH holds a Wellcome Trust Research Training Fellowship (097962/Z/11/Z). AVSH and SID are Jenner Investigators [Intr: <a href="http://www.jenner.ac.uk/">http://www.jenner.ac.uk/</a> ]. SB is a NDM Leadership Fellow ( <a href="http://www.ndm-ox.ac.uk/">http://www.ndm-ox.ac.uk/</a> ) and Junior Research Fellow of St Catherine's College, Oxford University ( <a href="http://www.stcatz.ox.ac.uk/">http://www.stcatz.ox.ac.uk/</a> ). SID is a UK MRC Career Development Fellow (G1000527) and Later Institute Research Prize Fellow ( <a href="http://www.later.institute.org.uk/">http://www.later.institute.org.uk/</a> ). The funders had no role in study design, data collection and analysis, decision to	N/A	N/A	N/A	N/A	10/12/2020
Betts G	Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunisation, controlled human malaria infection and natural exposure	2014	Plos One	SB was funded by Malaria Training, an FP6-funded Marie Curie Action under contract number MEST-CT-2005-020492. The G1A work was supported in part by the PATH-MVI Malaria Vaccine Initiative (MVI) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases and in part by the EMVDA (European Malaria Vaccine Development Association, a European Commission FP6-funded consortium). AAM is funded by UK Medical Research Council (U117632067). AVSH and SCG are Jenner Investigators and are funded by the Wellcome Trust. SID is a Junior Research Fellow at NetHERa College, Oxford University.	The authors have read the journal's policy and have the following conflicts: AVSH, AAP, and HM are named inventors in a patent filing related to MVASASA and are shareholders in a joint venture, OETC, formed for the future development of this vaccine. AVSH and HM are named as co-inventors on patents related to heterologous prime-boost immunisation. There are no other conflicts of interest. These conflicts of interest will not in any way interfere with the authors' adherence to the journal's policies on sharing data and materials.	N/A	N/A	10/12/2020	
Biswas S	Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1	2011	Plos One	This study was funded by the UK NIHR Biomedical Research Centre (BRC) with additional support from the Wellcome Trust.	SCGC, KAC, AVSH and SID are named inventors on patent applications covering malaria vaccines and immunization regimens (Adenoviral vectors encoding a pathogen or tumour antigen, WO/2008/122811; Viral vector immunogenic compositions, GB1016473.1). This does not alter the authors' adherence to PLoS ONE policies on sharing data and materials.	NCT01095055, NCT01003314, NCT01142765, NCT0080760	N/A	10/12/2020	
Biswas S	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP	2018	Scientific Reports	This research project was supported in part by funding from NIHR/NIAD CEIRS (HHSN27201400008C), and by grants awarded to C.L., including the US-Gateways to Health Women in Science (GWS) 2017 Neil Morindy and Monique Braude Fellowship, a UK Royal Society for Tropical Medicine and Hygiene small grant (GR000526), and by a Medical Research Fund pump-priming grant from the University of Oxford (MR/R172015/2/15/0). Unpublished.	SID, SCG and AVSH are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. Authors from Okairo are employees of and/or shareholders in Okairo, which is developing vectored malaria vaccines. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	N/A	N/A	10/12/2020	
Bliss CM Bliss CM	Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice	2020	Molecular Therapy	This study was funded by the UK NIHR Biomedical Research Centre (BRC) with additional support from the Wellcome Trust. This research project was supported in part by funding from NIHR/NIAD CEIRS (HHSN27201400008C), and by grants awarded to C.L., including the US-Gateways to Health Women in Science (GWS) 2017 Neil Morindy and Monique Braude Fellowship, a UK Royal Society for Tropical Medicine and Hygiene small grant (GR000526), and by a Medical Research Fund pump-priming grant from the University of Oxford (MR/R172015/2/15/0). Unpublished.	ADrian Hill and Sarah Gilbert are named inventors on patent applications and patents relating to malaria vectored vaccines and immunization regimens. Stefano Colocca and Alfredo Nicosia are employees of and/or shareholders in NetHERa, which is developing vectored vaccines for malaria and other diseases.	NCT01364883, 2010-023824-26	N/A	10/12/2020	
	Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1	2014	Molecular Therapy	The work was supported by Medical Research Council (MRC) UK and Department for International Development UK through an Experimental Medicine call 1 award 0702669 with contributions from the International AIDS Vaccine Initiative. HIV-1 infectious mo-lecular clones were obtained from Dr George Shaw, University of Pennsylvania. The HIV Control Preceptor Pool was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH (ref. no. 13626).	A.V.S.H. is named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and is a co-founder of, consultant to and shareholder in Vaccitech plc, which is developing Ad-vectored vaccines. The remaining authors declare no competing interests. A.N. and S.C. who were employees and shareholders of Okairo and Advent during the conduct of the study, and are inventors on patents WO 2005071093 (A3), WO 2006133911 (A3) and WO 03031588 (A2), J.J.MCM. who reports grants from MRC and NIH, personal fees from International AIDS Vaccine Initiative G1A during the conduct of the study and is an inventor on patent WO 06123256, L.C. reports grants from MRC during the conduct of the study, and T.H. who reports grants from MRC and European and Developing Countries Clinical Trial Preceptor Pool obtained during the conduct of the study and is an inventor on patent WO 06123256. The other authors declare no conflict of interest.	No ID found	Tried searching clinicaltrials.gov but could not find registered trial and not in study	16/12/20	

Bowyer G	Activation-induced Markers Detect Vaccine-Specific CD4 <sup>+</sup> T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials	2018	Vaccines	The clinical trial was supported by funding from an Enhancement Award to a Wellcome Trust Strategic Award (to AVSH as PI) co-funded by the UK Medical Research Council, the UK Department for International Development and the European and Developing Countries Clinical Trials Partnership, with additional funding from the NIHR Oxford Biomedical Research Centre. The Oxford clinical trial was supported by funding from a Wellcome Trust Strategic Award (to A.V.S. Hill as principal investigator) cofunded by the UK Medical Research Council, the UK Department for International Development, and the European and Developing Countries Clinical Trials Partnership, with additional funding from the National Institute for Health Research Oxford Biomedical Research Centre. GlaxoSmithKline Biologicals SA supplied the ChAd3-EBO-Z vaccine and had the opportunity to review this manuscript. The MVA-EBO-Z vaccine was biomanufactured for these trials by Regent Biosciences under a contract from Oxford University with funding from the same Enhancement Award. The Senegalese trial was largely funded by a European Commission Horizon 2020 program award, EbolaVac ( <a href="http://www.ebolavac.eu">http://www.ebolavac.eu</a> ), grant agreement no. 666805.	A.V.S.H. is a named inventor on patents relating to viral vectored vaccines. All other authors declare no conflicts of interest.	NCT02451891, 2015-000593-3	N/A	21/12/2020
Bowyer G	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+HLA3G1+ T cells Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus	2020	JEM	This work was supported by Biotechnology and Biological Sciences Research Council (BBSRC) grants BB/H010556/1 and BB/H010738/1. Jayne Hope and Irene McGuinness were supported by Institute Strategic Grant funding from the BBSRC.	N/A	NCT02451891	N/A	18/12/20
Boyd AC	Immunity, safety and protection of an Adenovirus 5 prime-Modified Vaccinia Virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves	2013	Elsevier - Vaccine	The Biotechnology and Biological Sciences Research Council and Wellcome Trust are gratefully acknowledged for their financial support.	N/A	N/A	N/A	16/12/20
Bull TJ	Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh3 and MVA prime-boost immunisation in non-human primates	2014	Veterinary Research	This work was supported by Biotechnology and Biological Sciences Research Council (BBSRC) grants BB/H010556/1 and BB/H010738/1. Jayne Hope and Irene McGuinness were supported by Institute Strategic Grant funding from the BBSRC.	TJB is a minor shareholder in HAV Vaccines Ltd.	N/A	N/A	20/12/2020
Capone S	ST4 oncofetal glycoprotein: an old target for a novel prostate cancer immunotherapy	2010	Elsevier - Vaccine	This work was supported by the Wellcome Trust. AVSH is a Wellcome Trust Principal Research Fellow.	N/A	N/A	N/A	16/12/20
Cappuccini F	Safety and immunogenicity of novel ST4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial	2017	Oncotarget	This work was supported by Oxford National Institutes for Health Research (NIHR) Biomedical Research Centre, UK (IR); the UK Medical Research Council CIG award (SS), the UK Wellcome Trust Senior Investigator's Award (AVSH) and the European Union's Seventh Framework Programme under grant agreement No. 602705 (FC, EP).	N/A	N/A	N/A	21/12/2020
Cappuccini F	Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer	2020	Cancer Immunol Immunother	The VANCE clinical trial was supported by the European Union's Seventh Framework Programme under grant agreement no. 602705.	AVSH is a co-founder of and shareholder in Vacitech Ltd which has supported the Oxford prostate cancer vaccine programme.	NCT02390063	N/A	18/12/20
Cappuccini F	Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route	2016	Cancer Immunol Immunother	This work was supported by Enterprise Ireland (Commercialisation Fund, CT1007117) and Science Foundation Ireland (National Access Programme 70 and 170). AVSH and SID are Jenner investigators, and SID is a UK MRC Career Development Fellow (G1000527) and Lister Institute Research Prize Fellow.	The authors declare no competing financial interests. AVSH and SID are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. JBC, AV, COM, AVSH, ACM are named inventors on patent applications covering microneedle-mediated vaccine delivery.	N/A	N/A	21/12/2020
Carey JB		2014	Scientific Reports	This work was supported by Enterprise Ireland (Commercialisation Fund, CT1007117) and Science Foundation Ireland (National Access Programme 70 and 170). AVSH and SID are Jenner investigators, and SID is a UK MRC Career Development Fellow (G1000527) and Lister Institute Research Prize Fellow.	The authors declare no competing financial interests. AVSH and SID are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. JBC, AV, COM, AVSH, ACM are named inventors on patent applications covering microneedle-mediated vaccine delivery.	N/A	N/A	16/12/20
Collica S	Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species	2012	Science Translational Medicine	This work was supported in part by Hepacvac (LSH-2005-1.2.4.2 project 037435) and the Wellcome Trust. A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship. E.B. was supported by Medical Research Council (UK) Author	N/A	N/A	N/A	16/12/2020
Colston JM	Modification of Antigen Impacts on Memory Quality after Adenovirus Vaccination	2016	The Journal of Immunology	This work was supported by Wellcome Trust Grants 099897/2/12/A and 091663MA.	N/A	N/A	N/A	20/12/2020
Cottingham MG	Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors	2012	Biotechnology and Bioengineering	This work was supported by the European Vaccine Initiative, the Oxford Martin School, the Gates Foundation through the Foundation for NIH, The Wellcome Trust, and the NIHR Oxford Biomedical Research Centre. We are grateful to Dr. Alexandra J. Spencer, Jenner Institute, University of Oxford, for assistance with immunology; to Mr. Jake Matthews, Vector Core Facility, Jenner Institute, University of Oxford, for assistance with ChAd3-Flu230; and to Dr. Nicola K. Green and Dr. Eleanor Berrie of the Clinical Biomanufacturing Facility, University of Oxford, for assistance and advice. Dr. David H. Wylie, Jenner Institute, University of Oxford performed some sequencing steps.	Conflict of interest: Okairo's Sri and the University of Oxford hold intellectual property related to adenovirus vaccine vectors.	N/A	N/A	16/12/20
Coughlan L	Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults	2018	Elsevier	Medical Research Council UK, NIHR BMRC Oxford.	SG and AMI are co-founders of Vacitech, a company developing viral vectored vaccines including broadly cross-reactive influenza vaccines. SG holds stock in Sanofi/Pasteur which develops and markets influenza vaccines. HDG received a travel grant from Abbvie.	NCT01818362	N/A	18/12/20
de Barra E	A phase I study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS	2014	PLoS One	The study was funded by a grant from the European Vaccine Initiative (EVI) ( <a href="http://www.evacvaccine.eu/">http://www.evacvaccine.eu/</a> ). Antibody assays were performed at WRAIR and were funded by the Malaria Vaccine Initiative. This work was also supported by the UN National Institute of Health Research through the Oxford Biomedical Research Centre (A91301 AdultVaccines) and the Wellcome Trust (084113/Z/07/Z). SG and AVSH are Jenner Investigators. AVSH supported by a Wellcome Trust Principal Research Fellowship (45488/Z/05), and SHH holds a Wellcome Trust Research Training Fellowship (097940/Z/11/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	SG and AMI are co-founders of Vacitech, a company developing viral vectored vaccines including broadly cross-reactive influenza vaccines. SG holds stock in Sanofi/Pasteur which develops and markets influenza vaccines. HDG received a travel grant from Abbvie. The authors have read the journal's policy and have the following conflicts: AVSH and SG are named inventors on patent filings related to immunisation with vectored malaria vaccines, specifically WO2008/122769. None of these products have been commercialized. AN was an employee of Okairo AG at the time of the study. Okairo AG has since been acquired by GSK Vaccines, which now owns patents and patent applications related to simian adenoviruses. None of the authors have had any consultancies relevant to this paper. This conflict of interest does not alter these authors' adherence to all PLOS ONE publication sharing data and materials, as detailed online in the guide for authors.	NCT01492280	N/A	16/12/20
de Cassan SC	The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus	2011	The Journal of Immunology	S.C.d.C. is a Ph.D. student supported by the European Malaria Vaccine Development Association, a European Commission Framework Programme 6-funded consortium (Grant 027037506). This work was also partly supported by the Wellcome Trust (Grant 084113/Z/07/Z), the National Institute for Health Research Oxford Biomedical Research Centre, TRANOVAC, a European Commission Framework Programme 7-funded consortium infrastructure grant, and grants to C.E.C. and V.S.C. from the Department of Biotechnology, Government of India, and European Vaccine Initiative. C.E.C. is supported by a Tata Innovation Fellowship from the Department of Biotechnology, Government of India. A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship. S.C.G., A.V.S.H., and S.I.D. are Jenner Investigators. S.I.D. is a Medical Research Council Career Development Fellow (Grant G1000027).	Disclosures: S.C.d.C., E.K.F., A.D.D., A.M., S.C.G., A.V.S.H., and S.I.D. are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. The other authors have no financial conflicts of interest.	N/A	N/A	16/12/20
Dicks MD	Differential immunogenicity between HAdV5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice	2015	Scientific Reports	This work has been funded by a grant from the Wellcome Trust (095540/Z/11/Z). AVSH and SCG are Jenner Institute Investigators, AIS and MGC are James Martin Fellows.	MDID, SCG, AVSH, and MGC are named inventors on a patent application describing the ChAdOx1 vector (US201504766).	N/A	N/A	20/12/2020
Dicks MD	The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species	2015	Vaccine	This work has been funded by the Wellcome Trust (095540) with additional funding from the Foundation for the Historical Institute of Health through the Grand Challenges in Global Health Initiative (HILLISGCHG). MDID received additional funding from the European Malaria Vaccine Development Association (EMVDA). AVSH is a Wellcome Trust Principal Research Fellow. EG and BC were funded by the Biotechnology and Biological Sciences Research Council BBS/E/I/0001373, United Kingdom.	MDID, SCG, AVSH, and MGC are named inventors on a patent application describing the ChAdOx1 vector (PCT Application No. PCT/G82012/000467).	N/A	N/A	20/12/2020

		This work has been funded by grants from the Foundation for the National Institute of Health through the Grand Challenges in Global Health initiative with additional funding from the Wellcome Trust. MDID received additional funding from the European Malaria Vaccine Development Association (EMVDA). MGCS a fellow of the Oxford Martin School Institute for Vaccine Design. SCG is a Jenner Investigator. AVSH is Director of the Jenner Institute and the Wellcome Trust Principal Research Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Competing interests: MDID, SCG, AVSH, and MGCS are named inventors on a patent application describing the ChAdOx2/ChAdOx1 vector (GB PatentApplication No. 1108879.8). This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	N/A	N/A	16/12/20	
Dicks MD	A novel chimpanzee adenovirus vector with low human seroprevalence and improved systems for vector derivation and comparative immunogenicity. Enhancing blood stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.	2012 Plos One					
Draper SJ	Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle	2010 The Journal of Immunology	This work was funded by the Wellcome Trust and the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium. S.J.D. is a Junior Research Fellow of Merton College, Oxford, United Kingdom. S.C.G. and A.V.S.H. are Jenner investigators, and A.V.S.H. is also a Wellcome Trust Principal Research Fellow.	Disclosures: S.J.D., S.C.G., and A.V.S.H. are named inventors on patent applications covering malaria vector vaccines. S.C.G., A.V.S.H., and N. are named inventors of and/or shareholders in Okairis, which is developing vectored vaccines for malaria and other diseases.	N/A	16/12/20	
Dubal P	Analysis of human B cell responses following ChAdOx1 MVA MDPF and AMA1 immunisation and controlled malaria infection	2016 Vaccine	This study was conducted with support from a grant from the Bill & Melinda Gates Foundation Grand Challenges (exploratory initiative to GWB (09P108893)) and a Wellcome Trust fellowship to GMM (WT098635). B.C. and A.V.S.H. are Jenner Investigators.	N/A	N/A	20/12/2020	
Elias SC	Protective CD8 $\beta$ T cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation	2013 Immunology	This work was supported by the UK Medical Research Council (grant number G0700733); the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium (LSHM-CT-2007-037266); the UK National Institute of Health Research through the Oxford Biomedical Research Centre; the Wellcome Trust (0841131/Z/07/Z); and by EVMIa1a funded by the European Community's Seventh Framework Programme (FP7/2007-2013) (Grant agreement No. 242095). AVSH and ID are Jenner Investigators; and SID is a UK MRC Career Development Fellow (1000527) and Lister Institute Prize Research Fellow.	SCG, KAC, AVSH and SID are named inventors on patent applications covering malaria vaccines and immunisation regimens.	NCT01373879, NCT01142765, NCT01003314, NCT01050505	N/A	20/12/2020
Ewer K	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA	2016 New England Journal of Medicine	Supported by the Wellcome Trust, the United Kingdom Medical Research Council, the United Kingdom Department for International Development, and the United Kingdom National Institute for Health Research Oxford Biomedical Research Centre. The National Health Service Blood and Transplant and Public Health England provided funding for the chimpanzee studies. The ChAdOx1 vaccine was provided by the Vaccine Research Centre of the National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline. MVA-BN File was produced under a contract (H5N2-004-099) between the NIAID and Fisher Scientific and a contract (H5N27220800044C) between the National Institutes of Health and Fisher BioServices.	Dr. Ballou, Dr. De Ryck report personal fees and other support from GlaxoSmithKline outside the submitted work. Dr. Collico, Dr. Cortese, Dr. Nicotia reports a pending patent related to chimpanzee adenoviral vector based filovirus vaccine (WO/2012/230627). Dr. Draper reports grant support from the UK Medical Research Council during the conduct of the study, and non-financial support from GlaxoSmithKline/Okairis outside the submitted work. In addition, Dr. Draper reports pending patents related to viral vector immunogenic compositions (WO 2012042779 A3) and adenoviral vectors encoding a pathogen or tumor antigen (WO 2008122811 A2). Dr. Gilbert reports patents related to prime boost immunization with viral vectors. Dr. Hill reports a patent related to heterologous prime-boost immunization, licensed to Oxford BioMedica. Ms. Lella reports other support from the NIHR during the conduct of the study. Dr. Levine reports grant support from Oxford University during the conduct of the study. Dr. Pollard reports grant support from the Wellcome Trust during the conduct of the study, and grant support from GlaxoSmithKline outside the submitted work.	N/A	N/A	20/12/2020
Ewer K Fedosyuk S	Protective CD8 $\beta$ T cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation	2013 Nature Communications	This study was funded by grants from the UK MRC/the NIHR through the Oxford Biomedical Research Centre, and the Wellcome Trust. AVSH was supported by Wellcome Trust Principal Research Fellowship. A.L.G. was supported by a grant from the MRC (G0603424). A.V.S.H., A.R.-S., S.J.D. and S.C.G. are Jenner Institute Investigators; A.V.S.H. is a Wellcome Trust and NIHR Senior Investigator.	Sarah Gilbert, Arturo Reyes-Sandoval, Anna Goodman, Geraldine O'Hara and Adrian Hill are named inventors on patent applications covering malaria vector vaccines and immunization regimens including: WO/2006/122811-Adenoviral vectors encoding a pathogen or tumor antigen and WO/2008/122769-Adenoviral vector encoding malaria antigen. Authors from Okairis are employees of/and/or share holders in Okairis which is developing vectored malaria vaccines. All other authors declare no competing financial interests.	N/A	N/A	16/12/20
Folgett P.M.	Simian adenovirus vector production for early-phase clinical trials: a simple method applicable to multiple serotypes and using entirely disposable product-contact components	2019 Elsevier Vaccine	This work was supported by Merck KGaA, the UK Medical Research Council (grant MR/P01739/1), and the UK Engineering and Physical Sciences Research Council (grant EP/R013754/1). ADD is supported by the Wellcome Trust (grants 204772/Z/16/Z and 204826/Z/16/Z) and is a Jenner Investigator. The study was performed in collaboration between the University of Oxford and Merck KGaA; both partners reviewed the manuscript prior to sub-issuance. The other funders had no input to the design of the study or decision to publish.	ADD, SIM, and SCG are named inventors on patent filings relating to the use of simian adenoviruses, but not directly related to work described here. SCG is a founder of Vaccitech Ltd, which develops adenovirus-vectored vaccines.	N/A	N/A	10/12/2020
Folgett P.M.	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial	2020 The Lancet	UK Department of Health and Social Care, using UK Aid funding, managed by the UK National Institute for Health Research. This project was funded by the UK Department of Health and Social Care (project number 16100703). The views expressed are those of the authors and not necessarily those of the Department of Health and Social Care. The work was supported by the UK National Institute for Health Research through the Oxford Biomedical Research Centre. The Coalition for Epidemic Preparedness Innovations provided funding for the extended 12 months of follow-up in this study. This study was also partially supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (Finance code 001). The pseudovirus neutralising antibody work was funded by a grant from the Korean Ministry of Health and Welfare (H15C2971)	AH and SG are co-founders of, consultants for, and shareholders in Vaccitech, which is developing adenoviral vectored vaccines. PMF and TL are consultants for Vaccitech. All other authors declare no competing interests.	NCT03399578	N/A	18/12/20
Folgett P.M. Folgett PM	Safety and immunogenicity of the ChAdOx1-nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	2020 The Lancet	UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and the German Centre for Infection Research (DZIF), Partner site Giessen-Marburg-Langen. This work is funded by UK Research and Innovation (MC_PC_2005), Engineering and Physical Sciences Research Council (EP/R01375/2), Coalition for Epidemic Preparedness Innovations (CEPI), the National Institute for Health Research (NIHR), the NIHR Oxford Biomedical Research Centre, and the German Centre for Infection Research (DZIF). Partner site Giessen-Marburg-Langen. Additional resources for study delivery were provided by NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; the NIHR Imperial Clinical Research Facility, and NIHR North West London, South London, Wessex, and West of England Local Clinical Research Networks and NIHR Oxford Health Biomedical Research Centre. PMF received funding from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (finance code 001). Development of SARS-CoV-2 reagents was partially supported by the US National Institute of Health (NIH) through the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NIHR, the NIHR or the Department of Health.	SGC is co-founder and board member of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on patent covering use of ChAdOx1 vectored vaccines and a patent application covering this SARS-CoV-2 vaccine. TL is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and consultant to Vaccitech. PMF is a consultant to Vaccitech. AHP is Chair of the UK Department of Health and Social Care's Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in policy advice on coronavirus vaccines, and is a member of the WHO Strategic Advisory Group of Experts (SAGE). AVSH is a co-founder of and consultant to Vaccitech and is named as an inventor on a patent covering design and use of ChAdOx1 vectored vaccines. AF is a member of JCVI, Chair of the WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health Research West of England Local Clinical Research Network. KMF reports grants from the NIHR Imperial Biomedical Research Centre and Glaxo Sciences, and personal fees from Sanofi Pasteur, outside of the submitted work. MS reports grants from Janssen, GlaxoSmithKline, MedImmune.	NCT04324606. The study is ongoing, and in preparation of interests says royalties paid to A2 for vectors.	18/12/20	
Forbes EK	T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of CD4-binding protein. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimens	2012 Plos One	This work was supported primarily by grant G0600424 from the Medical Research Council (ALG) and in addition by Transmolebio (EU FP7) and BBSRC (award number I0AD_P15820). SID and AVH are Jenner Investigators. SID is a MRC Career Development Fellow. AVH is a Wellcome Trust Principal Research Fellow. ALG was an MRC clinical training fellow whilst she undertook this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. <a href="http://www.mrc.ac.uk/index.htm">http://www.mrc.ac.uk/index.htm</a> . <a href="http://www.bbsrc.ac.uk/">http://www.bbsrc.ac.uk/</a>	J.H., T. is the Chief Scientific and Medical Officer for HAV Vaccines Ltd. S.C.G. and A.V.S.H. are co-founders of, consultants to and shareholders in Vaccitech plc which is developing adenoviral vectored vaccines.	NCT03027193	N/A	18/12/20
Gilbert SC Gola A	Prime and target immunization protects against liver-stage malaria in mice	2002 Elsevier - Vaccine	Wellcome Trust and the European Commission (I18-CT95-0019 TMR Fellowship to J.S.) for support	A.H. is funded by the Wellcome Trust and by the Intramural Program of NIAID (NIH). B.R.H. is funded from the European Union Seventh Framework Programme FP7/2013-23816 under grant agreement 316655 (VAC1BRAN). A.V.S.H. is a Wellcome Trust and National Institute of Health Research (NIHR) senior investigator. This work was part funded by a Wellcome Trust Senior Investigator award (to A.V.S.H.) and a Wellcome Trust Enhancement award (to A.V.S.H.) for the clinical trial and also was supported in part by the Intramural Research Program of NIAID (NIH) (to R.N.G. and S.J.). The clinical trial was supported in part by funding from the UK NIHR Oxford Biomedical Research Centre.	N/A	N/A	14/12/20
Goodman AL	A viral vectored prime-boost immunization regime targeting the malaria PfPR2-10 antigen induces transmission-blocking activity	2011 Plos One	This work was supported primarily by grant G0600424 from the Medical Research Council (ALG) and in addition by Transmolebio (EU FP7) and BBSRC (award number I0AD_P15820). SID and AVH are Jenner Investigators. SID is a MRC Career Development Fellow. AVH is a Wellcome Trust Principal Research Fellow. ALG was an MRC clinical training fellow whilst she undertook this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. <a href="http://www.mrc.ac.uk/index.htm">http://www.mrc.ac.uk/index.htm</a> . <a href="http://www.bbsrc.ac.uk/">http://www.bbsrc.ac.uk/</a>	A.V.S.H., A.G., A.A.W., and A.M.S. are inventors on a patent application PCT/GB2017/051009 submitted by the Oxford University Innovation Limited that covers prime and target vaccination with viral vectors	N/A	N/A	21/12/2020

		This study was supported by UKRI Engineering and Physical Sciences Research Council (EPSRC) award EP/R013756/1 (VaxHub), UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme and Core Capabilities Grants to The Pirbright Institute (BBS/E/1/00007033, BBS/E/1/00007034, BBS/E/1/00007035, and BBS/E/1/00007036), and the Bill and Melinda Gates Foundation supported Pirbright Livestock Antibody Hub (Grant No. OPP215550). Development of SARS-CoV-2 reagents was partially supported by the NIAD Centers of Excellence for Influenza Research and Surveillance (CERS) contract HHSN172014000206C and EPSC Grant No. EP/S023243/1 to the Rosalind Franklin Institute. A.L., G.W., C.B., A.B. and V.M. are supported by the UK Department for Environment Food & Rural Affairs. We thank V. Clark, H. Gray, and R. Smith for animal husbandry and the Jenner Institute Vector Core for virus production, and The Pirbright Institute Animal Services Team for animal care and provision of samples.					
Graham SP	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19	2020 Nature partner journals	BRH received funding from the European Union Seventh Framework Programme FP7/2012-2016 under grant agreement n° 316653 (VACTRAIN). Additional funding was provided by the Wellcome Trust Senior Investigator award to AVSH and a Wellcome Trust Strategic Award supporting the viral vector core facility. Further funding was provided by a Gates Grand Challenges in Global Health award through the Foundation for NIH (to AVSH). This work was supported by the EMVAC (European Malaria Vaccine Development Association), a European Commission (EC) FP6-funded consortium (LSHP-CT-2007-037506); the UK National Institute of Health Research through the Oxford Biomedical Research Centre (grant 493303 Adult Vaccine); the Wellcome Trust (084113/2/07/2); and EVIMAR, an EC FP7-funded programme (Grant agreement No. 242095). The GIA work was supported by the PATH Malaria Vaccine Initiative and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.				
Halbroth BR	Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8(+) T Cell Responses	2018 Scientific Reports	This work was supported by the PATH Malaria Vaccine Initiative, the United Kingdom National Institute of Health Research through the Oxford Biomedical Research Centre (grant 493303 Adult Vaccine), and the Wellcome Trust (grants 084113/2/07/2 and 45488/2/05 to A.V.S.H. and grant 097940/2/12 to S.H.H.).				
Hodgson SH	Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase Ia clinical trial	2014 Molecular Therapy	Supported by a Medical Research Council (MRC) UK Development Clinical Scheme award (G0701694); by the Wellcome Trust, the Oxford NIHRRC, and the US19 grant (ZU19A026206, 26, to C.K. and P.K.); by an MRC CASE studentship (to L.S.). E.B. is funded as an MRC Senior Clinical Scientist and is supported by the Oxford NIHR BRC, the Oxford Martin School, and the Jenner Institute.				
Hodgson SH	Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME TRAP against controlled human malaria infection in malaria-naïve individuals	2015 The Journal of Infectious Diseases					
Kelly C	Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans	2016 Hepatology	This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), a four- and a half year integrated project funded by the European and Developing Countries Clinical Trials Partnership (EDCTP; grant number 2P020201). A.V.S.H. is an employee of the European Vaccine Initiative (EVI). E.V.I. is the coordinator of the EDCTP funded MVVC project (grant number SP_2008_31100_001). E.V.I. supports salaries of the MVVC project in kind. The work was also supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbrc.org/) (A91301 Adult Vaccine), the Wellcome Trust (http://www.wellcome.ac.uk/) (084113/2/07/2) and the Medical Research Council. S.H.H. holds a Wellcome Trust research training fellowship (097940/2/12/2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.				
Kimani D	Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naïve to malaria-endemic populations	2014 Molecular Therapy					
Lambe T	Immunity against heterologous influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1	2013 Scientific Reports	AVI was funded by a fellowship of the Dr. Saal van Zwabenbergh Stichting. Dr. Lambe is supported by the Oxford Martin School. S.C.G. is a Jenner Investigator.				
Longley RJ	Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates	2015 Scientific Reports	This work has been funded by a grant from the Wellcome Trust (095540/2/11/2) with additional funding by the Rhodes Trust and a Nuffield Department of Medicine Studentship to support RIL and EVIMAR studentship to support AMS. AVSH is a Jenner Institute Investigator; AS is a James Martin Fellow. CJ is supported by a grant of the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement number 242095.				
Longley RJ	Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine	2017 Infection and Immunity	Funding for manufacture and quality control release and stability studies of Samaria's P5P2 challenge was provided by the National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov) under grant R44AI083873 (Universal Attenuated Malaria Sporozoite Vaccine and Challenge System). The present work was funded by a grant from the Wellcome Trust (grant 095540/2/11/2) to A.V.S.H., with additional funding by the Rhodes Trust and a Nuffield Department of Medicine Studentship to support R.J.L. The human CHMI study (VAC049) was supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbrc.org/) (A91301 adult vaccine program) and the Wellcome Trust (grant 084113/2/07/2). B.R.H. receives funding from the European Union Seventh Framework Programme FP7/2012-2016 under grant agreement 216653 (VACTRAIN). S.H.H. is a Wellcome Trust Clinical Research Fellow (grant 097940/2/12/2). A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.				
López-Camacho McMahon M	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors	2018 Nature Communications	This report is independent research funded by the UK Department of Health and Social Care through Innovate UK "New vaccines for global epidemics: development and manufacture" grant No. 972216 (A.R.S.), and also funded from an ODA budget (Global Health (ODA), 16/10705—Design, development and GMP manufacture of a Zika vaccine) (A.K.P. and A.R.S.). The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care. We also acknowledge funding by the UK Medical Research Council [MC_UU_12014 (A.K.P. and A.K.) and MR/N017552/1 (A.K.)]. Juthathip Mongkolkeha is supported by an MRC-Newton Fund grant. Gavin Sraetan is a Wellcome Trust Senior Investigator.				
Mensah VA	Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge	2019 Vaccine	The study was funded by an MRC Biomedical Catalyst DPFS DCS award (MR/N06372/1). In addition, this study was partially funded by the NIAD Centers of Excellence for Influenza Research and Surveillance contract (CIERS), HHSN272014000086, grant A1109946 and grant A142046-01.				
Mensah VA	Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial	2017 Frontiers in Immunology	This work was supported by a Strategic Primer grant award from the European and Developing Countries Clinical Trials Partnership (EDCTP; grant number SP.2011.41304.025); with co-funding from Swedish International Development Cooperation Agency (Sida), UK Medical Research Council (Ink Aid, Department of Foreign Trade, Ireland), and Bundesministerium für Bildung und Forschung (BMBF), Germany. European Vaccine Initiative (EVI) coordinated the project under phase two of Malaria Vectored Vaccines Consortium (MVVC-2). Additional funding for the Oxford collaborators was provided by the Wellcome Trust and the UK National Institute of Health Research.				
Munster VJ	Protective efficacy of a novel simian adenovirus vaccine against lethal MERs-CoV challenge in a transgenic human DPP4 mouse model	2017 NPJ Vaccines	This study was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), an integrated project funded by EDCTP (grant number BEIR-2008.31100.001). Co-funding was also provided by the Medical Research Council UK, the Swedish International Development Cooperation Agency (Sida) and Ink Aid. The work was also supported by the Bakar University Cheikh Anta Diop.				
			This work is published with the permission of the Director of the Kenya Medical Research Institute, and was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAD), National Institutes of Health (NIH) and a grant from the UK Medical Research Council Confidence in Concept scheme to GWM through the LSTM Tropical Infectious Disease Consortium.				
				S.C.G. and T.L. are named on a patent application covering ChAdOx1 nCoV-19. The remaining authors declare no competing interests. The funders played no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.	N/A	N/A	18/12/20
				A.V.S.H. is a named investigator on US 12/595 574 and UK PCT/GB2008/01262 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimens; A.V.S.H., A.J.S., M.J.C. and B.R.H. are named investigators on UK PCT/GB2014/053596, a novel molecular adjuvant application.	N/A	N/A	10/12/2020
				D.D., J.L.J., S.C.d.C., A.V.S.H., and S.J.D. are named inventors on patent applications covering malaria vaccines and immunization regimens. A.N. is an employee of and/or shareholder in Okairo, which is developing vectored vaccines for malaria and other diseases.	NCT01351948	N/A	20/12/2020
				A. V. S. H. and S. C. G. are named inventors on patent applications covering malaria vectored vaccines and immunization regimens. S. C. and A. N. are employees of and/or shareholders in Okairo, which is developing vectored vaccines for malaria and other diseases. All other authors report no potential conflicts.	NCT01623557	N/A	20/12/2020
				Dr. Collins, Dr. Folgar, Dr. Cortese, and Dr. Ntossa are named inventors on patent applications covering hepatitis C virus-vectored vaccines and chimpanzee adenovirus vectors (WO 2006133911 [A]) hepatitis C virus nucleic acid vaccine, WO 2005071091 [A] chimpanzee adenovirus vaccine carrier, WO 09013368 [A2] hepatitis C virus vaccine). Dr. Hill is a coinventor on patent filings and applications related to heterologous prime-boost immunizations.	NCT01094873, 2008-006127-32	N/A	20/12/2020
				A.V.S.H. is a named inventor on patent applications on malaria vectored vaccines and immunization regimens. Authors from Okairo are employees of and/or shareholders in Okairo, which is developing vectored vaccines for malaria and other diseases.	N/A	N/A	16/12/20
					N/A	N/A	16/12/20
				AVSH is a named investigator on US 12/595 574 and UK PCT/GB2008/01262 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimens; RIL, AMS, CJ, SMK, AS and AVSH are named investigators on filed patent (1318084.9) for novel malaria antigens N/A	N/A	N/A	20/12/2020
				A.V.S.H. is a named investigator on novel adenovirus patent applications U.S. 12/595 574 and UK PCT/GB2008/01262, covering malaria vectored vaccines and immunization regimens. R.J.L., A.J.S., and A.V.S.H. are named investigators on patent PCT/GB2014/053077, identifying novel malaria vaccine antigens.	NCT01465048	N/A	21/12/2020
				A. R. S. and C. L. C. are co-inventors of the Zika vaccines described in this manuscript, filed by Oxford University Innovation Limited in the International Patent Application No. PCT/GB2017/022220 Zika Vaccine; A.V.S.H. and S.C.G. are co-inventors on a patent application (WO/2012/122277) on the ChAdOx1 viral vector filed by Oxford University Innovation. The remaining authors declare no competing interests.	N/A	N/A	21/12/2020
				The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines with P&F being inventor. SG is an inventor on patents covering ChAdOx1 and MVA NP+ M1, filed and owned by the University of Oxford, and is a co-founder of and consultant to Vaccitech, a University of Oxford spin-out company which is undertaking advanced clinical development of viral vectored influenza vaccines.	N/A	N/A	10/12/2020
				The following authors have declared that no conflict of interest exists: VM, SR, EK, AMH, FO, CB, GB, YI, RR, NV, FD, OL, AL, BF, BK, SC, SG, EC, KE, EJ, and MA. AH is a named inventor on patent applications on malaria vectored vaccines and immunization regimens. RC and AN are employees of and/or shareholders in ReThera, which develops vectored vaccines for malaria and other diseases. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer AL declared a past collaboration with four of the authors, OL, NV, FD, and AH, to the handling Editor.	NCT02083887	N/A	21/12/2020
				We have the following interests. Adrian V.S. Hill is a named inventor on patent applications and patents on malaria vectored vaccines and immunization regimens including the following (WO/2008/122769, Adenoviral vector encoding malaria antigen; and WO 2008/122811 Novel adenovirus vectors). Egevan Imoukhuede and Ines Petersen were employees of EVI at the time of the study which supports the development and testing of malaria vaccines. Nicola Velighe is an employee of EVI and Odile Leroy is executive director of EVI. Authors from Re Thera (formerly Okairo) are employees of and/or shareholders in Re Thera, which is developing vectored vaccines for malaria and other diseases. Alfredo Ntossa was employed by Re Thera (formerly Okairo) at the time of the study.	PACTR2011-303-000-409-409; (African Pan Trial Registry)	N/A	21/12/2020
				S.C.G. is a co-founder of, consultant to and shareholder in Vaccitech plc, which is developing a vectored MERS vaccine. Remaining authors declares that they have no competing financial interests.	N/A	N/A	21/12/2020

Nébié I	Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors	2014	Clinical and Vaccine Immunology	This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), an integrated project funded by EDCTP grant number#P-2008.31100.001.	N/A	N/A	N/A	16/12/20
O'hara GA	Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector	2011	The Journal of Infectious Diseases	Financial support. This work was supported by an Experimental Medicine grant from the UK Medical Research Council (grant number G0600318) with additional support from the UK National Institute for Health Research Oxford Biomedical Research Centre and the Wellcome Trust. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	NCT00890019	N/A	N/A	16/12/20
Ogwang C	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults	2015	Science Translational Medicine	This work was funded by the European and Developing Countries Clinical Trials Partnership, grant number #P-2008.31100.002, to the Malaria Vectored Vaccines Consortium (MVVC), and coordinated by the European Vaccine Initiative (EVI). P.B. is jointly funded by the U.K. Medical Research Council (MRC) and the U.K. Department for International Development (DfID) under the MRC/DfID Concordat agreement.	NCT01666925, PACTA 20120200356308	N/A	N/A	20/12/2020
Ogwang C Payne RO	Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults	2013	Plos One	This work was performed by the Malaria Vectored Vaccines Consortium (MVVC), a four year integrated project funded by the European and Developing Countries Clinical Trials Partnership (EDCTP). The work was also supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbrc.org/) (A18101 Adult Vaccines), the Wellcome Trust (http://www.wellcome.ac.uk/) (084113/2/07/2) and the Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Competing interests: AH is a named inventor on the following patent applications on malaria vectored vaccines and immunization regimens (WO/2008/122969, Adenoviral vector encoding malaria antigens, and WO/2008/122811 Novel adenovirus vectors). Authors from Okairo's are employees of and/or shareholders in Okairo's, which is developing vectored vaccines for malaria and other diseases. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	NCT01379640	N/A	16/12/20
	Human vaccination against Plasmodium via Duffy-binding protein induces strain-transcending antibodies	2017	JCI Insight	This work was supported by a UK Medical Research Council (MRC) grant (number G1100086). The study was also supported in part by UK National Institute of Health Research (NIHR) infrastructure through the NIHR Oxford Biomedical Research Centre and the Wellcome Trust (084113/2/07/2). It was supported by the Rhodes Trust. TAR holds a Wellcome Trust Research Training Fellowship (108734/2/15/2). SCGC was a PhD student supported by the European Malaria Vaccine Development Association, a European Commission Framework Programme 6-funded consortium (grant LSHP-CT-2007-037506). TDO is supported by the Wellcome Trust (WT 098053). JSM is supported by an NIHR MRC Practitioner Fellowship (number 1041802). AVSH and SID are Jenner investigators. SID is a Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow (grant number 106917/2/15/2).	S.C. de Cassan, M.K. Higgins, A.V.S. Hill, and S.J. Draper are named inventors on patent applications (patent nos. GB1413530.5, GB1016471.3, and WO/2008/122811) covering malaria vaccines and immunization regimens. A. Nicosia was an employee of and shareholder in Okairo's (since acquired by GlaxoSmithKline), which is developing vectored vaccines for a number of diseases. T. Jørgensen and W.A. de Jongh are employees of, and W.A. de Jongh is a shareholder in, Expression Biotechnologies, which has developed and is marketing the Expre2 cell expression platform. C.E. Chitnis is a named inventor on a patent covering PvcPB_RII (patent no. WO/1996/040766).	NCT01816113	N/A	21/12/2020
	Human vaccination against RHS induces neutralising antiserum antibodies that inhibit RfS invasion complex interactions	2017	JCI Insight	This work was supported by funding from the European Union Seventh Framework Programme (FP7/2007-2013) under the grant agreement for MultiMVAx (number 305282). The study was also supported in part by UK NIHR infrastructure through the NIHR Oxford Biomedical Research Centre, the MAVARE-CA program funded by Danida (the Consultative Committee for Development Research, Denmark), and the Wellcome Trust (grant numbers 084113/2/07/2 and 206194). The GAT work was supported by the United States Agency for International Development (USAID) through the Intramural Program of the NIH, National Institute of Allergy and Infectious Diseases. DGWA holds a UK MRC CASE PhD Studentship (MR/R017632/2). JSM is supported by a National Health and Medical Research Council (NH&MRC) Practitioner Fellowship (number 1041802). AVSH and SID are Jenner Training Fellowship and Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow (106917/2/15/2).	S.J. Draper is a named inventor on patent applications relating to RfS and/or other malaria vaccines and immunization regimens; is a cofounder of, shareholder in, and consultant for SpyBioTech, and declares research funding support from Pfizer and GSK Biopharm. A.D. Douglas, L.J. Wright, and A.V.S. Hill are named inventors on patent applications relating to RfS and/or other malaria vaccines and immunization regimens. L. Siani and S. Di Marco are employees of RelThera (formerly Okairo), which is currently developing vectored vaccines for a number of diseases. J. Vekemans was an employee of GSK, which has acquired the ChAd63 vector from Okairo. R. Ashfield is a director of Duocinis and holds shares in the company, which is developing a therapy for autoimmune disease. A.M. Mianassian has an immediate family member who is an inventor on patents relating to RfS and/or other malaria vaccines and immunization regimens and who is a cofounder of, shareholder in, and consultant for SpyBioTech. S. Biswas is a cofounder and CEO of, and shareholder in, SpyBioTech and is a contributor to a patent application relating to multimerisation technology. J. Jin is a cofounder and shareholder in SpyBioTech.	NCT02181088	N/A	21/12/2020
	Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice	2013	Plos One	This work has been supported by a UK Medical Research Council Capacity Building Studentship (G0600311, www.mrc.ac.uk) and by the Bill and Melinda Gates Foundation (003436, www.gatesfoundation.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Competing Interests: Authors MLC, GIFF, XC and MAFK are either inventors or contributors to a patent filings related to the Nanopatch™ technology, that is now licensed to Vaxxas Pty Ltd. These are detailed in Supporting Information - Table S2. Authors MLC, SDF, GIFF and MAFK have employment with Vaxxas. MAFK is a member of the Vaxxas board. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	N/A	N/A	16/12/20
	Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine A multi-antigenic adenovirus-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression	2015	Vaccine	This study was funded by Enterprise Ireland (CTD07/117 http://www.enterprise-ireland.com), Science Foundation Ireland (NAP15andNAP17), www.sfi.ie and the Medical Research Council, United Kingdom (G0600311, www.mrc.ac.uk).	None	N/A	N/A	20/12/2020
Pérez de Val B	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP	2013	Plos One	The study was funded by the European Community's 7th Framework Programme (FP7-4BBE-2007-1-9-04: TB-STEP project under grant agreement124244). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	N/A	N/A	N/A	16/12/20
Rampling T	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP	2016	The Journal of Infectious Diseases	This work was supported by the PATH Malaria Vaccine Initiative and by the United Kingdom NIHR, through the NIHR Oxford Biomedical Research Centre, the Southampton NIHR Wellcome Trust Clinical Research Facility, and the Imperial College NIHR Wellcome Trust Clinical Research Facility.	NCT01883609	N/A	N/A	20/12/2020
Rampling T	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP	2018	Nature partner journals	This work was funded primarily by the PATH Malaria Vaccine Initiative (MVI); in addition, the work was supported by the United Kingdom National Institute of Health Research (NIHR) infrastructure, through the NIHR Oxford Biomedical Research Centre, the Southampton NIHR Wellcome Trust Clinical Research Facility, and the Imperial College NIHR Wellcome Trust Clinical Research Facility; the NIHR CRF and BRC at Imperial College Healthcare NHS Trust. Viewers expressed are those of the author(s) and not necessarily those of PATH MVI, the NIHR, the NIHR, or the Department of Health.	A.V.S.H. and S.C.G. are named inventors on patent applications and patents relating to malaria vectored vaccines and immunization regimens. D.M. J.M.L. and R.W.B. are employees of GSK, which is developing vaccines for malaria and other diseases. S.N.F. acts on behalf of the University of Southampton/University Hospital Southampton National Health Service Foundation Trust as chief and principal investigator for clinical trials sponsored by vaccine manufacturers, including GSK, but receives no personal payments for the work.	NCT02252640	N/A	18/12/20
Reyes-Sandoval A	Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses	2010	Human Vaccines	Work in the Oxford malaria vaccine program is supported by the Wellcome Trust, the UK Medical Research Council, the UK National Institute for Health Research through the Oxford Biomedical Research Centre, the European Commission, the Gates Foundation through a Grand Challenges in Global Health award from the Foundation for NIH, the European Malaria Vaccine Initiative, the Jenner Vaccine Foundation and the European and Developing Countries Clinical Trials Partnership.	N/A	N/A	N/A	10/12/2020
Reyes-Sandoval A	Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antibody immunity	2010	The American Society of Gene & Cell Therapy	We thank the Jenner Institute's vector core facility for providing the vectored vaccines, and Dr. Helen McShane for providing the ad-enzoviral and MVA vectors expressing antigen 85A. We are also grateful to Andrew Williams for providing the P. berghei parasites and the NIH tetramer facility (MNC tetramer core facility, Emory University Vaccine Center, Atlanta, GA) for preparing the P39 tetramer. The transgenic parasites were kindly provided by Dr Oliver Blikker from Wellcome Trust Sanger Institute, Hinxton, UK. This work was funded by Wellcome Trust Principal Research Fellowship award, Grant Number: 076438, the National Institute for Health Research Oxford Biomedical Research Centre Program and Grand Challenges in Global Health. A.R.-S. is a Scientific Leadership Fellow of the Oxford Department of Medicine and a Wellcome Trust Fellow. C.S.K. is supported by NIHR Oxford Biomedical Research Centre, The Oxford Martin School and Meningitis UK.	N/A	N/A	N/A	16/12/20
Reyes-Sandoval A	Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei	2008	European Journal of Immunology	The work was supported by a Wellcome Trust Principal Research Fellowship award grant number 076438 to A.V.S.H.	N/A	N/A	N/A	16/12/20

Rollier CS			This work was funded by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative of the Gates Foundation, with additional support from the Wellcome Trust. Non-human primate studies were supported by National Center for Research Resources (NCRR) grant # P51 RR000167, and were conducted at a facility constructed with support from grants RR15450 and RR020141. The authors wish to acknowledge the expert contribution of Dr Matthew G. Cottingham, and the expert help provided by the Animal Services Unit, and the Immunology Services Unit of the Wisconsin National Primate Research Center, in particular D. Watkins and E. Rakasz. It is supported by the NIHR Biomedical Research Centre, Oxford, CR, SGC and AVSH are Jenner Institute investigators and AVSH is a Wellcome Trust and NIHR Senior Investigator. The funding sources had no involvement in study design; collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the article for publication.	A.V.S.H. and S.G.C. are names as co-inventors on patents related to recombinant viral vectors for malaria and other indications.	N/A	N/A	18/12/20
Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule	2020 Nature		he work was funded by a Wellcome Trust Career Development Fellowship award, grant number 097395/2/12/2, to A.R., who is also a Jenner Investigator and an Oxford Martin Fellow. Funding was also provided by the Medical Research Council, through a DPFS grant (MR/N019008/1) to A.R., S. Ahmed M. Salman was funded by EVMalaria's Program funding (FP7/2007–2013) under grant agreement N° 242095. Adrian Hill is supported by a Wellcome Trust grant number 095540/2/11/2 and is a Jenner Investigator and an Oxford Martin Fellow.	N/A	N/A	N/A	21/12/2020
Salman AM	2017 Scientific Reports	Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector	This research was funded by Innovate UK (Novel multivalent vaccines against haemorrhagic fevers,971510) and MRC (Confidence in Concept CK 2015-16, MC_PC_15040, Liverpool School of Tropical Medicine). This work was supported by the European Malaria Vaccine Development Association (EMVDA), a European Commission FP6-funded consortium ( <a href="http://www.emvda.org/">http://www.emvda.org/</a> ) [LSHP-CT-2007-037506]; the UK National Institute of Health Research through the Oxford Biomedical Research Centre ( <a href="http://www.oxfordbrc.org/">http://www.oxfordbrc.org/</a> ) [A91301 Adult Vaccine] and the Wellcome Trust ( <a href="http://www.wellcome.ac.uk/">http://www.wellcome.ac.uk/</a> ) [084113/2/07/2]. The GIA work was supported by the PATH Malaria Vaccine Initiative (MVI) ( <a href="http://www.malariaivaccine.org/">http://www.malariaivaccine.org/</a> ) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases ( <a href="http://www.niaid.nih.gov/Pages/default.aspx">http://www.niaid.nih.gov/Pages/default.aspx</a> ). CIAD holds a Wellcome Trust Research Training Fellowship [RT10]; S.G.C., AVSH and SID are Jenner investigators; AVSH was supported by a Wellcome Trust Principal Research Fellowship [05488/2/05]; and SID is a UK Medical Research Council Career Development Fellow [G1000257]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	N/A	N/A	N/A	18/12/20
Sebastian S	2020 MDRP		This work was supported by the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium ( <a href="http://www.emvda.org/">http://www.emvda.org/</a> ) [LSHP-CT-2007-037506]; the UK National Institute of Health Research through the Oxford Biomedical Research Centre ( <a href="http://www.oxfordbrc.org/">http://www.oxfordbrc.org/</a> ) [A91301 Adult Vaccine] and the Wellcome Trust ( <a href="http://www.wellcome.ac.uk/">http://www.wellcome.ac.uk/</a> ) [084113/2/07/2]. The GIA work was supported by the PATH Malaria Vaccine Initiative (MVI) ( <a href="http://www.malariaivaccine.org/">http://www.malariaivaccine.org/</a> ) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases, S.C.G., A.V.S.H., and S.J.D. are Jenner investigators; A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship [05488/2/05]; C.I.A.D. holds a Wellcome Trust Research Training Fellowship [094449/2/10/2]; and S.J.D. is a UK Medical Research Council Career Development Fellow [G1000257]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Competing interests: AIS, MDID, SGC, AVSH and SID are named inventors on US 12/595 574 and UK PCT/GB2008/01262, US 12/995 951 and UK PCT/GB2008/01271 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimes. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. Authors from Okara's are employees of and/or shareholders in Okara, which is developing vectored vaccines for malaria and other diseases. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.	N/A	N/A	18/12/20
Sheehy SH	2012 Plos One	Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors	This work was supported by the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium (LSHP-CT-2007-037506); the UK Medical Research Council (grant no. G0700735); the UK National Institute of Health Research through the Oxford Biomedical Research Centre (A91301 Adult Vaccine); and the Southampton NIHR Wellcome Trust Clinical Research Facility; the Wellcome Trust (084113/2/07/2); and EVMalaria, an European Commission FP7-funded programme (grant agreement no. 242095). The growth inhibitory activity work was supported by the PATH Malaria Vaccine Initiative (MVI) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases, S.C.G., A.V.S.H., and S.J.D. are Jenner investigators; A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship [05488/2/05]; C.I.A.D. holds a Wellcome Trust Research Training Fellowship [094449/2/10/2]; and S.J.D. is a UK Medical Research Council Career Development Fellow [G1000257]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Competing interests: AIS, MDID, SGC, AVSH and SID are named inventors on US 12/595 574 and UK PCT/GB2008/01262, US 12/995 951 and UK PCT/GB2008/01271 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimes. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. Authors from Okara's are employees of and/or shareholders in Okara, which is developing vectored vaccines for malaria and other diseases. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.	N/A	N/A	16/12/20
Sheehy SH	2012 Therapy	ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans	This work was supported by the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium (LSHP-CT-2007-037506); the UK National Institute of Health Research through the Oxford Biomedical Research Centre (A91301 Adult Vaccine) and the Southampton NIHR Wellcome Trust Clinical Research Facility; the Wellcome Trust (084113/2/07/2); and EVMalaria, an European Commission FP7-funded programme (grant agreement no. 242095). The growth inhibitory activity work was supported by the PATH Malaria Vaccine Initiative (MVI) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases, S.C.G., A.V.S.H., and S.J.D. are Jenner investigators; A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship [05488/2/05]; C.I.A.D. holds a Wellcome Trust Research Training Fellowship [094449/2/10/2]; and S.J.D. is a UK Medical Research Council Career Development Fellow [G1000257]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Competing interests: AIS, MDID, SGC, AVSH and SID are named inventors on US 12/595 574 and UK PCT/GB2008/01262, US 12/995 951 and UK PCT/GB2008/01271 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimes. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. Authors from Okara's are employees of and/or shareholders in Okara, which is developing vectored vaccines for malaria and other diseases. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.	N/A	N/A	16/12/20
Sheehy SH	2011 The Journal of Immunology	Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors	This work was supported by the European Malaria Vaccine Development Association, a European Commission FP6-funded consortium (LSHP-CT-2007-037506); the UK National Institute of Health Research through the Oxford Biomedical Research Centre (A91301 Adult Vaccine) and the Southampton NIHR Wellcome Trust Clinical Research Facility; the Wellcome Trust (084113/2/07/2); and EVMalaria, an European Commission FP7-funded programme (grant agreement no. 242095). The growth inhibitory activity work was supported by the PATH Malaria Vaccine Initiative (MVI) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases, S.C.G., A.V.S.H., and S.J.D. are Jenner investigators; A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship [05488/2/05]; C.I.A.D. holds a Wellcome Trust Research Training Fellowship [094449/2/10/2]; and S.J.D. is a UK Medical Research Council Career Development Fellow [G1000257]. A.R.W., S.G.C., A.V.S.H., and S.J.D. are named inventors on patent applications covering malaria vectored vaccines and immunization regimes. Authors from Okara's are employees of and/or shareholders in Okara's which is developing vectored vaccines for malaria and other diseases.	Competing interests: AIS, MDID, SGC, AVSH and SID are named inventors on US 12/595 574 and UK PCT/GB2008/01262, US 12/995 951 and UK PCT/GB2008/01271 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimes. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. Authors from Okara's are employees of and/or shareholders in Okara, which is developing vectored vaccines for malaria and other diseases. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.	N/A	N/A	16/12/20
Spencer AJ Stedman A	2014 Plos One	Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class II invariant chain	This work has been funded by grants from the Foundation for the National Institute of Health through the Grand Challenges in Global Health Initiative (HLLSG5G5WH) with additional funding from the Wellcome Trust (095546/2/11/2). Non-human primate studies were supported by National Center for Research Resources (NCRR) grant #P51 RR000167, and was conducted at a facility constructed with support from grants RR15450 and RR020141. The funding bodies did not have a role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. Co-authors S. Capone, S. Colloca, A.F. RC and AN are employees of Okara's. Okara's provided support in the form of salaries for the authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the 'author contributions' section.	AVSH is a named inventor on WO/2008/122811 Adenoviral vectors encoding a pathogen or tumour antigen and WO/2008/122769-Adenoviral vector encoding malaria antigen. S. Colloca, A.F. RC, and AN are named inventors on patent application WO 2005071093 (A3) Chimpzee adenovirus vaccine carriers. Authors from Okara's were employees of and/or share holders in Okara's, this does not alter the authors' adherence to all the PLOS ONE policies sharing data and materials.	N/A	N/A	16/12/20
	2019 Nature partner journals	Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats	This study was funded by the UK Department of Health and Social Care [UK DHSC Project 16/107/03]. G.M.W. is supported by an Oak foundation fellowship and a Wellcome Trust grant (203077_2_16_2). S.G.C., B.C. and A.V.S.H. are Jenner investigators. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this publication are those of the authors and do not necessarily reflect those of the UKDHSC. We thank Dr. Connie Schmaljohn [USAMRIID, Fort Detrick, MD] for providing the rA24 antibody. This paper is published with the permission of the Pirbright Institute and the Director of the Kenya Medical Research Institute.	S.G.C. and A.V.S.H. are co-founders of, consultants to and shareholders in Vectozield, which is developing ChAdOx1-vectored vaccines. The remaining authors declare no competing interests.	N/A	N/A	18/12/20
	2018 Nature partner journals	An Ad/MVA vectored Theileria parva antigen induces schizont-specific CD8(+) central memory T cells and confers partial protection against a lethal challenge	This work was funded by the Bill and Melinda Gates Foundation (BMGF) and the Department for International Development (DFID) of the United Kingdom (PP170791), the Norman Borlough Commemorative Research Initiative, an initiative between the Feed the Future program of United States Agency for International Development (USAID), USA and United States Department of Agriculture (USDA)-Agricultural Research Service, USA (58-5348-2-117F) and through funding from the CGIAR Research Program on Livestock and Fish (CRP 3.7)	Competing interests: S. Colloca, A.F., R.C., and A.N. are named inventors on patent applications covering HCV-vectored vaccines and chimpanzee adenovirus vectors [WO 200613931 (A3)] hepatitis C virus nucleic acid vaccine, WO 2005071093(A3) chimpanzee adenovirus vaccine carriers, WO 03031888 (A2) hepatitis C virus vaccine]. P.K. has acted as a consultant to Tbiotech and Pfizer on antiviral therapy. The other authors declare they have no competing interests.	N/A	N/A	18/12/20
	2014 Science Translational Medicine	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory	Funding supported by the Medical Research Council (MRC) UK and the European Union [Framework VI: HEPACVAC] for funding the study and the manufacture of MVA-NSmut through an MRC UK DC3 (Developmental Clinical Studies) award. E.B. is supported by the MRC as a Senior Clinical Fellow, the Oxford Martin Schools, and National Institute for Health Research Oxford Biomedical Research Centre. L. Swadlow is supported by an MRC CASE studentship. Supported by the Medical Research Council (MRC) and the European Union [Framework VI: HEPACVAC] for funding the study and the manufacture of MVA-NSmut through an MRC UK DC3 (Developmental Clinical Studies) award [G07101694]. Christabell Kelly and Paul Kieneman are supported by the Wellcome Trust, the Oxford NIHR BRC, and the US grant (U19AI062930). Swadlow is supported by an MRC CASE studentship. Eleanor Barnes is funded as an MRC Senior Clinical Fellow, and is supported by the Oxford NIHR BRC, the Oxford Martin School and the Jenner Institute.	Competing interests: S. Colloca, A.F., R.C., and A.N. are named inventors on patent applications covering HCV-vectored vaccines and chimpanzee adenovirus vaccine carriers, WO 200613931 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093 (A3) chimpanzee adenovirus vaccine carriers, WO 03031888 (A2) hepatitis C virus vaccine]. Adrian Hill is a co-inventor on patent filings and applications related to heterologous prime-boost immunizations.	N/A	N/A	16/12/20
	2016 Vaccines		This study was funded by a Wellcome Trust Strategic Translation Award, with funding contributions from the Medical Research Council UK, and the Department for International Development UK supported the primary vaccination of 80 Malian participants with ChAd3-EBO-Z. A Wellcome Trust Enhancement Award funded the boosting of 52 Malians with MVA-BN-Filo or saline. Funding for priming immunisation of the Malian participants with the ChAd3-EBO-Z vaccine and for data management was provided by the National Cancer Institute, the National Cancer Laboratory for Cancer Research, Federal Funds from the National Institute of Allergy and Infectious Diseases, and a contract (number HHSN26320080001E) awarded to Linds Biomedical Research. The US trial was funded by the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, through a contract to the EMMES Corporation.	Stefano Colloca, Antonella Folgori, Riccardo Cortese and Alfredo Nicolis are named inventors on patent applications covering HCV-vectored vaccines and chimpanzee adenovirus vaccine carriers, WO 200613931 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093 (A3) chimpanzee adenovirus vaccine carriers, WO 03031888 (A2) hepatitis C virus vaccine]. Adrian Hill is a co-inventor on patent filings and applications related to heterologous prime-boost immunizations.	NCT01296451	N/A	20/12/2020
	2016 The Lancet Infectious Diseases	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial	This study was funded by a Wellcome Trust Strategic Translation Award, with funding contributions from the Medical Research Council UK, and the Department for International Development UK supported the primary vaccination of 80 Malian participants with ChAd3-EBO-Z. A Wellcome Trust Enhancement Award funded the boosting of 52 Malians with MVA-BN-Filo or saline. Funding for priming immunisation of the Malian participants with the ChAd3-EBO-Z vaccine and for data management was provided by the National Cancer Institute, the National Cancer Laboratory for Cancer Research, Federal Funds from the National Institute of Allergy and Infectious Diseases, and a contract (number HHSN26320080001E) awarded to Linds Biomedical Research. The US trial was funded by the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, through a contract to the EMMES Corporation.	FR, IDR, and WRB are employees of GlaxoSmithKline and manufacture non-replicating chimpanzee adenovirus 3-based vaccines. NS is a named inventor on patents covering adenovirus vector (WO) is named as an inventor on patents using heterologous prime boost immunisation with viral vectors, such as those assessed in this report. MML serves as a member of the Scientific Advisory Working Group to the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, and of the Vaccine Research Center Board of Scientific Counselors.	NCT02231866, NCT02267109	N/A	20/12/2020

Tiono AB	First field efficacy trial of the ChAd63 MVA ME-TMNP vectored malaria vaccine candidate in 5-17 months old infants and children	2018	Plos One	This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), a 5-year integrated project (Grant number IP_2008.31100.001). The European Vaccine Initiative (EVI) was the coordinator of the EDCTP-funded MVVC project. Co-funding was also provided by the Swedish International Development Cooperation Agency (SIDA), the Austrian Federal Ministry of Science and Research, and Irish Aid. Additional support for the Oxford clinical trials team was provided by the UK NIHR through the Oxford Biomedical Research Centre	: AVSH is a named inventor on patent applications and issued patents relating to malaria vectored vaccines and immunization regimes. This does not alter the author's adherence to all the PLOS ONE policies on sharing data and materials.	NCT01635647; PACTR202120800404131	N/A	21/12/2020
Tuthill M.	Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA S14 (VLP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer	2020	Annals of Oncology (Abstracts)	European Union Seventh Framework Programme under grant AgreementNo. 602705 (Project IMPROVE) and Vaccitech Ltd.				18/12/20
Utrilla-Trigo S	Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus	2020	MDPI	This work was supported by grants AGL2017-85570-R from the Spanish Ministry of Science and Innovation, 2020 Program (European Commission Grant Agreement NO. 727393-RIE-6EU), SLT as a recipient of apredocctoral fellowship from the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Centro de Investigación en Sanidad Animal (program FPI-SG17-201).	N/A	N/A	N/A	18/12/20
van Doremalen N van Doremalen N	A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques A single dose ChAdOx1 vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters	2020	Science Advances	This work was supported by the intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (12DAI001179-01) and the Department of Health and Social Care using UK Aid funding managed by the NIHR. S.C.G. is a Jenner investigator. The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care.	S.C.G. is a board member of Vaccitech and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines. The other authors declare that they have no competing interests.	N/A	N/A	18/12/20
van Doremalen N Venkattaman N	ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques	2020	Nature	This work was supported by the intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (12DAI001179-01) and the Department of Health and Social Care using UK Aid funding managed by the NIHR. This work was supported by the Wellcome Trust, the UK Medical Research Council, the UK Department for International Development, and the UK NIHR Oxford Biomedical Research Centre. The Good Manufacturing Practice biomanufacture of MVA-EB0-2 and the UK clinical trial was supported by an Enhancement Award to a Wellcome Trust Strategic Award (to A. V. S. H. as principal investigator) co-funded by the Medical Research Council, the Department for International Development, and the European and Developing Countries Clinical Trials Partnership (grant number 130625/2/14/A), with additional support from the NIHR Oxford Biomedical Research Centre. The Senegal trial was largely funded by a European Commission Horizon 2020 program award EboVAc (www.ebovac.eu, grant agreement 646085), which provided additional resources for the MVA-EB0-2 biomanufacture. This study was also supported by GlaxoSmithKline Biologicals SA.	S.C.G. is a board member of Vaccitech and named as an inventor on a patent covering the use of ChAdOx1-vector based vaccines and a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). T.L. is named as an inventor on a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). The University of Oxford and Vaccitech, having joint rights in the vaccine, entered into a partnership with AstraZeneca in April 2020 for further development, large-scale manufacture and global supply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Oxford University nor Vaccitech will receive any royalties during the pandemic period or from any sales of the vaccine in developing countries. The other authors declare no competing interests.	N/A	A2 in competing interests	18/12/20
Walker AS Wang C	Safety and immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines	2019	The Journal of Infectious Diseases	Andrew S. Walker, José Lourenço and Sunetra Gupta are funded by the European Research Council (ERC Advanced Grant—Diversity). AVSH is a Jenner Investigator and Wellcome Trust and NIHR Senior Investigator.	F. R. and W. R. B. are employees of GSK and own restricted shares of the company. S. C. G., K. E. L., and A. V. S. H. are named inventors on patents relating to viral vector vaccines for malaria and other diseases. F. R. and W. R. B. are employees of GSK, which is developing vectored vaccines for Ebola and other diseases. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.	NCT02451891; NCT02485912	N/A	18/12/20
Warimwe GM	A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis	2018	Plos Neglected Tropical Diseases	This work was supported by the UK Medical Research Council including Confidence in Concept (grants MC_PC_13072 and MR/P017339/1), SID, AVSH and ADD are Jenner Investigators; SID is also a Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow (grant 106917/2/15/2). ADD is supported by the Wellcome Trust (grant 200477/2/16/2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AVSH and ADD are named inventors on a patent application relating to the development of the ChAdOx2 vector. AVSH and SID are named inventors on a patent relating to the use of the intron-containing promoter used in ChAdOx2 RabG. The University of Oxford and the Wistar Institute have entered into a partnership to share any future revenue from development of the ChAdOx2 RabG vaccine.	N/A	N/A	21/12/2020
Warimwe GM Yoshida K	Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice	2016	Scientific Reports	This work was conducted with the support from the University of Oxford, a Wellcome Trust fellowship to GMW (WT098933) and grant from the Bill & Melinda Gates Foundation through the Grand Challenges Exploration Initiative to GMW (OPP1068983). B. C., S. C. G. and A. V. S. H. are Jenner Investigators.	N/A	N/A	N/A	20/12/2020
Warimwe GM Yoshida K	Adenovirus-prime and basolivirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model	2018	Scientific Reports	This work was supported, in part, by a Grant-in-Aid for Young Scientists (B) (JSPS KAKENHI grant number 20860278), a grant from the Chiyama Health Foundation, and Cooperative Research Grants from NKENH, OSA (grant number 6) and 2015 (grant number 27-3) to M. I., by Grants-in-Aid for Scientific Research (B) (JSPS KAKENHI grant numbers: 21390126 and 25300507) and a Grant-in-Aid for Challenging Exploratory Research (JSPS KAKENHI grant number 24659460) to S. Y., and by the UK Medical Research Council (award number MR/N022776/1) to A. M. B.	MD1D, MGC, SCG and AVSH are named inventors on a patent application describing the ChAdOx1 vector (GB Patent application number 1108879.6). All other authors declare that they have no competing interests. The authors have read the journal's policy and declare the following conflicts of interest: S. Y. and A. H. are named inventors on filed patents related to immunization with the B.D.E.S. (WO/2007/091424) and ChAd63 (WO/2008/122709) anti-malaria vaccines, respectively. Neither of these products has been commercialized. None of the authors have undertaken any consultancies relevant to this study. These conflicts of interest do not alter the authors' adherence to all the policies of Scientific Reports on sharing data and materials, as detailed online in the guide for authors.	N/A	N/A	21/12/2020

Award number	Funder name	Awardee (to whom was the grant?)	Date	Amount	Exchange rate	Amount in GBP	Relevant publications (author and date)	Direct citation from articles
-	AIDS Vaccine Initiative	-	-	-	-	-	Borthwick et al (2014)	The work was supported by
-	Austrian Federal Ministry of Science and	-	-	-	-	-	Tiono (2018)	This work was supported by a
BBS/E//00001373	BBSRC	<u>Bryan Charleston</u>	Jan 09 - Jan 13	£790,209		£ 790,209.00	Dicks et al (2015 - 2)	This work has been funded by
BB/H010556/1	BBSRC	<u>Tim Bull</u>	Mar 10 - May 13	£351,371		£ 351,371.00	Bull et al (2014)	This work was supported by B
BB/H010718/1	BBSRC	<u>Jayne Hope</u>	Sep 11 - Aug 13	£235,928		£ 235,928.00	Bull et al (2014)	This work was supported by B
-	BBSRC	Hope J	-	-	-	-	Bull et al (2014)	This work was supported by B
-	BBSRC	McGuines I	-	-	-	-	Bull et al (2014)	This work was supported by B
LDAD_P15820	BBSRC	-	-	-	-	-	Goodman et al (2011)	This work was supported prim
LDAD_P15820	BBSRC	-	-	-	-	-	Goodman et al (2011)	This work was supported prim
OPP1096893	Bill & Melinda Gates Foundation	<u>Warimwe GM</u>	-	-	-	-	Dulal et al (2016)	This study was conducted with
OPP1096893	Bill & Melinda Gates Foundation	Warimwe GM	-	-	-	-	Warimwe et al (2016)	This work was conducted with
OPP1078791	Bill and Melinda Gate Foundation	Research Institute	Oct-13	\$ 10,999,924	0.72	£ 7,919,945.28	Svitek (2018)	This work was funded by the t
OPP1215550	Bill and Melinda Gates Foundation	The Pirbright Institute	Nov-19	\$ 5,530,900	0.72	£ 3,982,248.00	S Graham (2020)	and the Bill and Melinda Gate
-	3436 Bill and Melinda Gates Foundation	-	-	-	-	-	Pearson et al (2013)	This work has been supported
-	Biotechnology and Biological Sciences Ri-	-	-	-	-	-	Boyd et al (2013)	The Biotechnology and Biolog
-	Bundesministerium für Bildung und Fors-	-	-	-	-	-	Mensah (2017)	This work was supported by a
-	Cancer Research	Malinauskas T	-	-	-	-	Bauza et al (2014)	The work was funded by a We
-	Cancer Research	Jones EY	-	-	-	-	Bauza et al (2014)	The work was funded by a We
-	CAPES	Atcheson E	-	-	-	-	Atcheson (2018)	The work was funded by a We
CRP 3.7	CGIAR Research Program on Livestock ar-	-	-	-	-	-	Svitek (2018)	This work was funded by the t
-	Coalition for Epidemic Preparedness Inn-	-	-	-	-	-	Folegatti P.M.(2020)	UK Department of Health and
finance code 001	Coordenacao de Aperfeicoamento de Pe:	Folegatti P.M	-	-	-	-	Folegatti P.M.(2020)	UK Department of Health and
finance code 001	Coordenacao de Aperfeicoamento de Pe:-	-	-	-	-	-	Folegatti P.M.(2020)	UK Department of Health and
-	Dakar University Cheikh Anta Diop	-	-	-	-	-	Mensah et al (2016)	This study was supported by a
-	Danida	-	-	-	-	-	Payne et al (2017)	This work was supported by fi
-	Department for Business, Energy and Industrial Strategy	-	-	£65,500,000.00	-	£ 65,500,000.00	<a href="https://www.imperial.ac.uk/news/197573/covid-19-vacc">https://www.imperial.ac.uk/news/197573/covid-19-vacc</a>	
-	Department for Business, Energy and Industrial Strategy	-	-	£20,000,000.00	-	£ 20,000,000.00	<a href="https://www.imperial.ac.uk/news/197017/imperial-covir">https://www.imperial.ac.uk/news/197017/imperial-covir</a>	
-	Department for International Developme-	-	-	-	-	-	Bowyer (2018)	The clinical trial was supporte
-	Department for International Developme-	-	-	-	-	-	Venkatraman N (2019)	This work was supported
-	Department of Biotechnology, Governm: Chauhan VS	-	-	-	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	Department of Biotechnology, Governm: Chitnis CE	-	-	-	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	Department of Foreign Affairs and Trade-	-	-	-	-	-	Mensah (2017)	This work was supported by a
-	DFID	-	-	-	-	-	Tapia et al (2016)	This study was funded by a W
-	DFID	-	-	-	-	-	Ewer et al (2016)	Supported by the Wellcome T
-	Division of Intramural Research	-	-	-	-	-	Forbes et al (2012)	This work was funded by the \
-	Dr. Saal van Zwanenberg Stichting	van Laarhoven A	-	-	-	-	Lambe et al (2013)	AVL was funded by a fellowsh
IP.2008.31100.00	EDCTP	-	-	-	-	-	Kimani et al (2014)	This work was supported by
IP.2008.31100.001	EDCTP	-	-	-	-	-	Afolabi et al (2016)	Trials Partnership (EDCTP) anc
IP.2008.31100.001	EDCTP	-	-	-	-	-	Mensah et al (2016)	This study was supported by a
IP.2008.31100.001	EDCTP	-	-	-	-	-	Nébié et al (2014)	This work was supported by a
-	EMVDA	Dicks MDJ	-	-	-	-	Dicks et al (2012)	This work has been funded by
-	EMVDA	Dicks MDJ	-	-	-	-	Dicks et al (2015 - 2)	This work has been funded by
-	EMVDA	-	-	-	-	-	Forbes et al (2012)	This work was funded by the \
LSHP-CT-2007-03750	EMVDA	-	-	-	-	-	Biswas et al (2014)	This work was supported by ti
LSHP-CT-2007-037506	EMVDA	-	-	-	-	-	Sheehy et al (2011)	This work was supported by ti
LSHP-CT-2007-037506	EMVDA	-	-	-	-	-	Sheehy et al (2012 - 2)	This work was supported by ti
LSHP-CT-2007-037506	EMVDA	-	-	-	-	-	Sheehy et al (2012)	This work was supported by
LSHP-CT-2007-037506	EMVDA	-	-	-	-	-	Hodgson et al (2014)	This work was supported by ti
2007-037506	EMVDA	-	-	-	-	-	Draper et al (2011)	SB was funded by MalParTrai



EP/R013756/1	Engineering and Physical Sciences Research Council	Tarit K Mukhopadhyay	Apr 18 - Sep 21	€6,968,179	£ 6,968,179.00	Folegatti P.M.(2020)	UK Department of Health and
CFTD07/117	Enterprise Ireland	-	-	-	-	Pearson et al (2015)	This study was funded by Enterprise Ireland
CFTD07/117	Enterprise Ireland	-	-	-	-	Carey et al (2013)	This work was supported by Enterprise Ireland
-	EU HEPACIVAC	-	-	-	-	Swadling (2016)	Supported by the Medical Research Council
-	European and Developing Countries Clinical Trials Partnership	-	-	-	-	Bowyer G (2020)	The Oxford clinical trial was supported by the Medical Research Council
-	European and Developing Countries Clinical Trials Partnership	-	-	-	-	Reyes-Sandoval (2010)	Work in the Oxford malaria vaccine trial was supported by the Medical Research Council
-	European and Developing Countries Clinical Trials Partnership	-	-	-	-	Bowyer (2018)	The clinical trial was supported by the Medical Research Council
-	European and Developing Countries Clinical Trials Partnership	-	-	-	-	Venkatraman N (2019)	This work was supported by the Medical Research Council
IP.2008.31100.001	European and Developing Countries Clinical Trials Partnership	-	-	-	-	Ogwang et al (2015)	This work was funded by the Medical Research Council
SP.2011.41304.025	European and Developing Countries Clinical Trials Partnership	-	-	-	-	Mensah (2017)	This work was supported by a grant from the Medical Research Council
IP.2008.31100.001	European and Developing Countries Clinical Trials Partnership	-	-	-	-	Tiono (2018)	This work was supported by a grant from the Medical Research Council
666085	European Commission	GLAXOSMITHKLINE BIOLOGICALS SA	07-Oct-14	€ 15,153,216	0.87 £ 13,183,297.92	Venkatraman N (2019)	This work was supported by the Medical Research Council
666085	European Commission	GLAXOSMITHKLINE BIOLOGICALS SA	07-Oct-14	€ 15,153,216	0.87 £ 13,183,297.92	Bowyer G (2020)	The Oxford clinical trial was supported by the Medical Research Council
242095	European Commission	Salman AM	01-Oct-09	€ 12,000,000	0.87 £ 10,440,000.00	Atcheson (2018)	The work was funded by a grant from the Medical Research Council
727393-PALE-Blue	European Commission	THE UNIVERSITY OF NOTTINGHAM	01-Jun-17	€ 6,039,301.50	0.87 £ 5,254,192.31	Utrilla-Trigo S (2020)	This work was supported by a grant from the Medical Research Council
602705	European Commission	-	-	€ 6,000,000	0.87 £ 5,220,000.00	Cappuccini F (2020)	The VANCE clinical trial was supported by the Medical Research Council
602705	European Commission	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	01-Apr-14	€ 6,000,000	0.87 £ 5,220,000.00	Tuthill M. (2020)	European Union Seventh Framework Programme
316655	European Commission	Halbroth BR	01-Nov-12	€ 3,060,467.67	0.87 £ 2,662,606.87	Halbroth (2018)	BRH received funding from the Wellcome Trust
316655	European Commission	Halbroth BR	-	-	-	Gola (2018)	A.G. is funded by the Wellcome Trust
-	European Commission	-	-	-	-	Reyes-Sandoval (2010)	Work in the Oxford malaria vaccine trial was supported by the Wellcome Trust and the European Union
IC18-CT95-0019	European Commission	Fellowship to author to J.S.	-	-	-	Gilbert et al (2002)	Wellcome Trust and the European Union
212414	European Community's 7th Framework Programme	UNIVERSIDAD COMPLUTENS DE MADRID	01-Oct-08	€ 2,894,759	0.87 £ 2,518,440.33	Pérez et al (2013)	The study was funded by the European Union
242095	European Community's Seventh Framework Programme	Janse CJ	-	-	-	Longley et al (2015)	This work has been funded by the Medical Research Council
242095	European Community's Seventh Framework Programme	-	-	€ 12,000,000	0.87 £ 10,440,000.00	Forbes et al (2012)	This work was funded by the Medical Research Council
-	European Malaria Vaccine Development	-	-	-	-	Draper et al (2010)	This work was funded by the Medical Research Council
LSHP-CT-2007-037506	European Malaria Vaccine Development	-	-	-	-	Elias et al (2013)	This work was supported by the Medical Research Council
LSHP-CT-2007-037506	European Malaria Vaccine Development	de Cassan SC	-	-	-	Payne (2017)	This work was supported by a grant from the Medical Research Council
LSHP-CT-2007-037506	European Malaria Vaccine Development	de Cassan SC	-	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supported by the Medical Research Council
-	European Malaria Vaccine Development	-	-	-	-	Capone et al (2010)	This work was supported by the Medical Research Council
-	European Malaria Vaccine Initiative	-	-	-	-	Reyes-Sandoval (2010)	Work in the Oxford malaria vaccine trial was supported by the Medical Research Council
-	European Research Council	Walker A	-	-	-	Walker et al (2015)	Andrew S. Walker, José Loureiro
-	European Research Council	Lourenço J	-	-	-	Walker et al (2015)	Andrew S. Walker, José Loureiro
-	European Research Council	Gupta S	-	-	-	Walker et al (2015)	Andrew S. Walker, José Loureiro
305282	European Union	MultiMalVax	01-Oct-12	€ 6,000,000	0.87 £ 5,220,000.00	Payne et al (2017)	This work was supported by the Medical Research Council
316655	European Union	Halbroth BR	-	-	-	Longley et al (2017)	Funding for manufacture and development of the vaccine
602705	European Union	Capuccini F	-	-	-	Capuccini et al (2017)	This work was supported by the Medical Research Council
602705	European Union	Pollock E	-	-	-	Capuccini et al (2017)	This work was supported by the Medical Research Council
Framework VI; HEPACIVAC	European Union	-	-	-	-	Barnes et al (2012)	European Union (Framework VI)
602705	European Union's Seventh Framework Programme	Capuccini F	01-Apr-14	€ 6,000,000	0.87 £ 5,220,000.00	Capuccini et al (2016)	This work was supported by the Medical Research Council
602705	European Union's Seventh Framework Programme	Pollock E	-	-	-	Capuccini et al (2016)	This work was supported by the Medical Research Council
-	European Vaccine Initiative	-	-	-	-	Cottingham et al (2012)	This work was supported by the Medical Research Council
-	European Vaccine Initiative	-	-	-	-	de Barra et al (2014)	The study was funded by a grant from the Medical Research Council
-	European Vaccine Initiative	Chauhan VS	-	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supported by the Medical Research Council
-	European Vaccine Initiative	Chitnis CE	-	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supported by the Medical Research Council
-	European Vaccine Initiative	Viebig NK	-	-	-	Kimani et al (2014)	This work was supported by the Medical Research Council
242095	EVIMalaria	-	-	-	-	Biswas et al (2014)	This work was supported by the Medical Research Council

242095	EVIMalaR	-	-	-	Elias et al (2013)	This work was supported by t		
242095	EVIMalaR	-	-	-	Hodgson et al (2014)	This work was supported by t		
242095	EVIMalaR	Salman M	-	-	Salman et al (2017)	The work was funded by a We		
242095	EVIMalaR	-	-	-	Sheehy et al (2012)	This work was supported by		
-	EVIMaIR	Salman AM	-	-	Longley et al (2015)	This work has been funded by		
-	Foundation to NIH	Hill A.V.S	-	-	Halbroth (2018)	BRH received funding from th		
-	Frederick National Laboratory for Cancer	-	-	-	Tapia et al (2016)	This study was funded by a W		
-	Gates Foundation	-	-	-	Reyes-Sandoval (2010)	Work in the Oxford malaria va		
-	Gates Foundation (through the foundati	-	-	-	Cottingham et al (2012)	This work was supported by t		
-	German Center for Infection Research	-	-	-	Folegatti P.M.(2020)	UK Department of Health and		
-	Graduate Women in Science	Coughlan L	-	-	Bliss (2020)	This research project was sup		
-	Grand Challenges in Global Health	-	-	-	Reyes-Sandoval et al (2010)	We thank the Jenner Institu		
24659460	Grant-in-Aid for Challenging Exploratory	Yoshida S	-	-	Yoshida Klyori (2018)	This work was supported, in p		
26860278	Grant-in-Aid for Young Scientists	-	-	-	Yoshida Klyori (2018)	This work was supported, in p		
21390126	Grants-in-Aid for Scientific Research	-	-	-	Yoshida Klyori (2018)	This work was supported, in p		
25305007	Grants-in-Aid for Scientific Research	-	-	-	Yoshida Klyori (2018)	This work was supported, in p		
-	GSK	-	-	-	Venkatraman N (2019)	This work was supported		
-	HAV Vaccines Ltd	-	-	-	Folegatti P.M. (2019)	This research was funded by t		
-	HEPACIVAC	-	-	-	Swadling et al (2014)	Funding:Supported by the Me		
LSH-2005-1.2.4-2 proje	Hepacivac	-	-	-	Colloca et al (2012)	This work was supported in p		
-	Imperial College NIHR Wellcome Trust C-	-	-	-	Ramplng et al (2016)	This work was supported by t		
971510	Innovate UK	The Jenner Institute, Universi	Apr 17 - May 18	£483,455	£	483,455.00	Sebastian S (2020)	This research was funded by I
FPI-SGIT-201	Instituto Nacional de Investigación y Tec	Utrilla-Trigo S	-	-	Utrilla-Trigo S (2020)	This work was supported by g		
-	Irish Aid	-	-	-	Afolabi et al (2016)	Trials Partnership (EDCTP) an		
-	Irish Aid	-	-	-	Mensah (2017)	This work was supported by a		
-	Irish Aid	-	-	-	Mensah et al (2016)	This study was supported by a		
-	Irish Aid	-	-	-	Tiono (2018)	This work was supported by a		
-	James Martin School for 21st Century, O-	-	-	-	Barnes et al (2012)	European Union (Framework'		
-	Jenner Institue	Gilbert SC	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup		
-	Jenner Institue	Hill AVS	-	-	Dicks et al (2012)	This work has been funded by		
-	Jenner Institue	Hill AVS	-	-	Sheehy et al (2012)	This work was supported by		
-	Jenner Institue	Gilbert SC	-	-	Sheehy et al (2012)	This work was supported by		
-	Jenner Institute	Reyes-Sandoval A	-	-	Atcheson (2018)	The work was funded by a We		
-	Jenner Institute	Hill A.V.S	-	-	Atcheson (2018)	The work was funded by a We		
-	Jenner Institute	Hill AVS	-	-	Bauza et al (2014)	The work was funded by a We		
-	Jenner Institute	Reyes-Sandoval A	-	-	Bauza et al (2014)	The work was funded by a We		
-	Jenner Institute	McShane H	-	-	Betts et al (2012)	Funding was provided by NEW		
-	Jenner Institute	Hill AVS	-	-	Betts et al (2012)	Funding was provided by NEW		
-	Jenner Institute	Reyes-Sandoval A	-	-	Betts et al (2012)	Funding was provided by NEW		
-	Jenner Institute	Hill AVS	-	-	Biswas et al (2014)	This work was supported by t		
-	Jenner Institute	Draper SJ	-	-	Biswas et al (2014)	This work was supported by t		
-	Jenner Institute	Hill AVS	-	-	Carey et al (2013)	This work wassupported by Er		
-	Jenner Institute	Gilbert SC	-	-	Carey et al (2013)	This work wassupported by Er		
-	Jenner Institute	Hill AVS	-	-	de Barra et al (2014)	The study was funded by a gr		
-	Jenner Institute	Gilbert SC	-	-	de Barra et al (2014)	The study was funded by a gr		
-	Jenner Institute	Hill AVS	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup		
-	Jenner Institute	Draper SJ	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup		
-	Jenner Institute	Gilbert SC	-	-	Dicks et al (2012)	This work has been funded by		
-	Jenner Institute	Hill AVS	-	-	Dicks et al (2015)	This work has been funded by		
-	Jenner Institute	Gilbert SC	-	-	Dicks et al (2015)	This work has been funded by		
-	Jenner Institute	Gilbert SC	-	-	Draper et al (2010)	This work was funded by the \		
-	Jenner Institute	Hill A.V.S.	-	-	Draper et al (2010)	This work was funded by the \		
-	Jenner Institute	Hill AVS	-	-	Dulal et al (2016)	This study was conducted witi		
-	Jenner Institute	Charleston B	-	-	Dulal et al (2016)	This study was conducted witi		

-	Jenner Institute	Hill AVS	-	-	Elias et al (2013)	This work was supported by tt
-	Jenner Institute	Draper SJ	-	-	Elias et al (2013)	This work was supported by tt
-	Jenner Institute	Hill AVS	-	-	Ewer et al (2013)	The study was funded by gran
-	Jenner Institute	Draper SJ	-	-	Ewer et al (2013)	The study was funded by gran
-	Jenner Institute	Gilbert SC	-	-	Ewer et al (2013)	The study was funded by gran
-	Jenner Institute	Reyes-Sandoval A	-	-	Ewer et al (2013)	The study was funded by gran
-	Jenner Institute	Hill AVS	-	-	Forbes et al (2012)	This work was funded by the \
-	Jenner Institute	Draper SJ	-	-	Forbes et al (2012)	This work was funded by the \
-	Jenner Institute	Draper SJ	-	-	Goodman et al (2011)	This work was supported prim
-	Jenner Institute	Hill A.V.S	-	-	Goodman et al (2011)	This work was supported prim
-	Jenner Institute	Barnes E	-	-	Kelly et al (2016)	Supported by a Medical Resez
-	Jenner Institute	Gilbert SC	-	-	Lambe et al (2013)	AVL was funded by a fellowsh
-	Jenner Institute	Hill AVS	-	-	Longley et al (2015)	This work has been funded by
-	Jenner Institute	Hill AVS	-	-	Longley et al (2017)	Funding for manufacture and
-	Jenner Institute	Hill A.V.S	-	-	Payne (2017)	This work was supported by a
-	Jenner Institute	Draper SJ	-	-	Payne (2017)	This work was supported by a
-	Jenner Institute	Hill AVS	-	-	Payne et al (2017)	This work was supported by fi
-	Jenner Institute	Draper SJ	-	-	Payne et al (2017)	This work was supported by fi
-	Jenner Institute	Biswas S	-	-	Payne et al (2017)	This work was supported by fi
-	Jenner Institute	Reyes-Sandoval A	-	-	Salman et al (2017)	The work was funded by a We
-	Jenner Institute	Hill AVS	-	-	Salman et al (2017)	The work was funded by a We
-	Jenner Institute	Gilbert SC	-	-	Sheehy et al (2011)	This work was supported by tt
-	Jenner Institute	Hill AVS	-	-	Sheehy et al (2011)	This work was supported by tt
-	Jenner Institute	Draper SJ	-	-	Sheehy et al (2011)	This work was supported by tt
-	Jenner Institute	Gilbert SC	-	-	Sheehy et al (2012 - 2)	This work was supported by tt
-	Jenner Institute	Draper SJ	-	-	Sheehy et al (2012 - 2)	This work was supported by tt
-	Jenner Institute	Draper SJ	-	-	Sheehy et al (2012)	This work was supported by
-	Jenner Institute	Gilbert S.C.	-	-	Stedman (2019)	This study was funded by the
-	Jenner Institute	Charleston B	-	-	Stedman (2019)	This study was funded by the
-	Jenner Institute	A.V.S Hill	-	-	Stedman (2019)	This study was funded by the
-	Jenner Institute	Barnes E	-	-	Swadling (2016)	Supported by the Medical Res
-	Jenner Institute	Hill AVS	-	-	Walker et al (2015)	Andrew S. Walker, José Loure
-	Jenner Institute	Hill A.V.S	-	-	Wang (2018)	This work has been supported
-	Jenner Institute	Draper AD	-	-	Wang (2018)	This work has been supported
-	Jenner Institute	Douglas SJ	-	-	Wang (2018)	This work has been supported
-	Jenner Institute	Hill AVS	-	-	Warimwe et al (2013)	This work was supported by a
-	Jenner Institute	Gilbert SC	-	-	Warimwe et al (2013)	This work was supported by a
-	Jenner Institute	Hill AVS	-	-	Warimwe et al (2016)	This work was conducted with
-	Jenner Institute	Gilbert SC	-	-	Warimwe et al (2016)	This work was conducted with
-	Jenner Institute	Charleston B	-	-	Warimwe et al (2016)	This work was conducted with
-	Jenner Institute	Hill AVS	-	-	Sheehy et al (2012 - 2)	This work was supported by tt
-	Jenner Institute	Gilbert S.C.	-	-	Alharbi (2019)	This study is funded by KAIMR
-	Jenner Institute	Douglas AD	-	-	Fedosyuk S (2019)	This work was supported by Iv
-	Jenner Institute	Rollier C	-	-	Rollier C (2020)	This work was funded by a gr
-	Jenner Institute	Hill A.V.S.	-	-	Rollier C (2020)	This work was funded by a gr
-	Jenner Institute	Gilbert S.C.	-	-	Rollier C (2020)	This work was funded by a gr
-	Jenner Institute	Gilbert S.C.	-	-	van Doremalen N (2019)	This work was supported by tt
-	Jenner Vaccine Foundation	-	-	-	Reyes-Sandoval (2010)	Work in the Oxford malaria ve
RC16/093	KAIMRC	Naif Khalaf Alharbi	-	-	Alharbi (2019)	This study is funded by KAIMR
HI15C2971	Korean Ministry of Health and Welfare	-	-	-	Folegatti P.M.(2020)	UK Department of Health and
-	Lister Institute	Draper SJ	-	-	Biswas et al (2014)	This work was supported by tt
-	Lister Institute	Draper SJ	-	-	Elias et al (2013)	This work was supported by tt
-	Lister Institute	Draper SJ	-	-	Payne (2017)	This work was supported by a
-	Lister Institute	Draper SJ	-	-	Payne et al (2017)	This work was supported by ft
-	Lister Institute	Draper SJ	-	-	Carey et al (2013)	This work was supported by Er

-	Lister Institute	Douglas SJ	-	-	-	Wang (2018)	This work has been supported
-	Malaria Vaccine Initiative	-	-	-	-	de Barra et al (2014)	The study was funded by a gr
-	Malaria Vectored Vaccines Consortium (-	-	-	-	-	Ogwang et al (2015)	This work was funded by the t
MEST-CT-2005-020492	MalParTraining	Biswas S	-	-	-	Draper et al (2011)	SB was funded by MalParTrai
G0600424	Medical Research Council	<a href="#">Anna Louise Goodman</a>	Sep 06 - Oct 09	£159,968	£ 159,968.00	Goodman et al (2011)	This work was supported prim
-	Meningitis UK	Rollier CS	-	-	-	Reyes-Sandoval et al (2010)	We thank the Jenner Institu
-	Merck KGaA	-	-	-	-	Fedosyuk S (2019)	This work was supported by M
-	Merton College, Oxford	Draper SJ	-	-	-	Draper et al (2010)	This work was funded by the \
-	Merton College, Oxford	Draper SJ	-	-	-	Draper et al (2011)	SB was funded by MalParTrai
-	MEWA, Saudi Arabia	-	-	-	-	Alharbi (2019)	This study is funded by KAIMR
-	MRC	-	-	-	-	Bowyer (2018)	The clinical trial was supporte
-	MRC	-	-	-	-	Coughlan L (2018)	Medical Research Council UK,
-	MRC	Juthathip Mongkolsapaya	-	-	-	Lopez-Camacho (2018)	This report is independent res
-	MRC	-	-	-	-	Mensah (2017)	This work was supported by a
-	MRC	Warimwe GM	-	-	-	Munster (2017)	This work is published withthe
-	MRC	-	-	-	-	Venkatraman N (2019)	This work was supported
MC_UU_12014	MRC	Patel AH, Kohl A	-	-	-	Lopez-Camacho (2018)	This report is independent res
MR/P017339/1	MRC	<a href="#">Alexander Donald Douglas</a>	Apr 17 - Mar 22	£2,228,194	£ 2,228,194.00	Fedosyuk S (2019)	This work was supported by M
MR/P017339/1	MRC	<a href="#">Alexander Donald Douglas</a>	Apr 17 - Mar 22	£2,228,194	£ 2,228,194.00	Wang (2018)	This work has been supported
MR/N019008/1	MRC	Reyes-Sandoval A	Aug 16 - Feb 22	£1,792,688	£ 1,792,688.00	Atcheson (2018)	The work was funded by a We
MR/N019008/1	MRC	Reyes-Sandoval A	Aug 16 - Feb 22	£1,792,688	£ 1,792,688.00	Salman et al (2017)	The work was funded by a We
G0701669	MRC	<a href="#">Tomas Hanke</a>	Oct 08 - Oct 12	£1,300,519	£ 1,300,519.00	Borthwick et al (2014)	The work was supported by
MR/L009528/1	MRC	<a href="#">Thomas Alexander Bowden</a>	Jan 14 - Dec 18	£1,144,287	£ 1,144,287.00	van Doremalen N (2019)	This work was supported by tf
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£ 1,104,645.00	Biswas et al (2014)	This work was supported by ti
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£ 1,104,645.00	Carey et al (2013)	This work wassupported by Er
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£ 1,104,645.00	Elias et al (2013)	This work was supported by ti
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£ 1,104,645.00	Sheehy et al (2012 - 2)	This work was supported by ti
G1100086	MRC	<a href="#">Simon Draper</a>	Jul 11 - Jun 14	£895,438	£ 895,438.00	Payne (2017)	This work was supported by a
G0700735	MRC	<a href="#">Adrian Hill</a>	Jan 08 - Dec 10	£748,840	£ 748,840.00	Biswas et al (2014)	This work was supported by ti
G0700735	MRC	<a href="#">Adrian Hill</a>	Jan 08 - Dec 10	£748,840	£ 748,840.00	Elias et al (2013)	This work was supported by ti
MR/N006372/1	MRC	<a href="#">Sarah Catherine Gilbert</a>	Mar 16 - May 18	£679,559	£ 679,559.00	Asthagiri Arunkumar (2019)	The study was fundedby an M
MC_PC_13073	MRC	<a href="#">Chas Bountra</a>	Mar 14 - Sep 15	£650,000	£ 650,000.00	Wang (2018)	This work has been supported
G0502018	MRC	<a href="#">Adrian Hill</a>	Oct 06 - Jan 09	£647,586	£ 647,586.00	O'Hara et al (2012)	Financial support. This work v
		<a href="#">Andrew Michael</a>					This work was supported, in p
MR/N00227X/1	MRC	<a href="#">Blagborough</a>	Jan 16 - Apr 19	£549,297	£ 549,297.00	Yoshida Klyori (2018)	
MC_PC_15040	MRC	<a href="#">Stephen Ward</a>	Mar 16 - Feb 18	£500,000	£ 500,000.00	Sebastian S (2020)	This research was funded by I
G0701694	MRC	<a href="#">Eleanor Barnes</a>	Aug 09 - Jul 12	£250,000	£ 250,000.00	Kelly et al (2016)	Supported by a Medical Resea
G0701694	MRC	<a href="#">Eleanor Barnes</a>	Aug 09 - Jul 12	£250,000	£ 250,000.00	Swadling (2016)	Supported by the Medical Res
MR/N017552/1	MRC	Kohl A	Jan 16 - Jan 19	£221,947	£ 221,947.00	Lopez-Camacho (2018)	This report is independent res
G0600424	MRC	SJD	-	-	£ 159,968.00	Goodman et al (2011)	This work was supported prim
G0600424	MRC	Goodman A	Sep 06 - Oct 09	£159,968	£ 159,968.00	Ewer et al (2013)	The study was funded by gran
-	MRC	-	-	-	-	Afolabi et al (2016)	Trials Partnership (EDCTP) anc
-	MRC	-	-	-	-	Antrobus et al (2014)	The study was funded by gran
-	MRC	-	-	-	-	Barnes et al (2012)	European Union (Framework '
-	MRC	Jones EY	-	-	-	Bauza et al (2014)	The work was funded by a We
-	MRC	Malinauskas T	-	-	-	Bauza et al (2014)	The work was funded by a We
-	MRC	-	-	-	-	Bowyer G (2020)	The Oxford clinical trial was s
-	MRC	Stribbling S	-	-	-	Capuccini et al (2016)	This work was supported by C
-	MRC	Stribbling S	-	-	-	Capuccini et al (2017)	This work was supported by C
-	MRC	Bartiromo M	-	-	-	Colloca et al (2012)	This work was supported in p
-	MRC	-	-	-	-	Ewer et al (2013)	The study was funded by gran
-	MRC	Draper SJ	-	-	-	Forbes et al (2012)	This work was funded by the \

-	MRC	Draper SJ	-	-	-	Goodman et al (2011)	This work was supported prim	
-	MRC	Goodman AL	-	-	-	Goodman et al (2011)	This work was supported prim	
-	MRC	Barnes E	-	-	-	Kelly et al (2016)	Supported by a Medical Rese	
-	MRC	-	-	-	-	Kimani et al (2014)	This work was supported by	
-	MRC	-	-	-	-	Mensah et al (2016)	This study was supported by a	
-	MRC	-	-	-	-	Ogwang et al (2013)	This work was performed by t	
-	MRC	-	-	-	-	Swadling (2016)	Supported by the Medical Res	
-	MRC	Swadling L	-	-	-	Swadling (2016)	Supported by the Medical Res	
-	MRC	Barnes E	-	-	-	Swadling (2016)	Supported by the Medical Res	
-	MRC	-	-	-	-	Swadling et al (2014)	Funding:Supported by the Mei	
-	MRC	Barnes E	-	-	-	Swadling et al (2014)	Funding:Supported by the Mei	
-	MRC	Swadling L	-	-	-	Swadling et al (2014)	Funding:Supported by the Mei	
-	MRC	-	-	-	-	Tapia et al (2016)	This study was funded by a W	
-	MRC	-	-	-	-	Ewer et al (2016)	Supported by the Wellcome T	
-	MRC	Swadling L	-	-	-	Kelly et al (2016)	Supported by a Medical Rese	
G0600311	MRC	-	-	-	-	Pearson et al (2013)	This work has been supported	
G0600311	MRC	-	-	-	-	Pearson et al (2015)	This study was funded by Ente	
G0600424	MRC	ALG	Sep 06 - Oct 09	£159,968	-	Goodman et al (2011)	This work was supported prim	
G0700735	MRC	-	-	-	-	Sheehy et al (2011)	This work was supported by tl	
G1000157	MRC	Draper SJ	-	-	-	Sheehy et al (2011)	This work was supported by tl	
G1000527	MRC	Draper SJ	-	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup	
MR/K017632/1)	MRC	Alanine DGW	-	-	-	Payne et al (2017)	This work was supported by fi	
U117532067	MRC	Holder AA	-	-	-	Draper et al (2011)	SB was funded by MalParTrai	
-	MRC and DFID	-	-	-	-	Afolabi et al (2016)	Trials Partnership (EDCTP) anc	
-	MRC and DFID	-	-	-	-	Afolabi et al (2016)	Trials Partnership (EDCTP) anc	
-	MRC and DFID	Bejon P	-	-	-	Ogwang et al (2015)	This work was funded by the f	
-	National Cancer Institute	-	-	-	-	Tapia et al (2016)	This study was funded by a W	
P51 RR000167	National Center for Research Resources	-	-	-	-	Rollier C (2020)	This work was funded by a gra	
RR020141	National Center for Research Resources	-	-	-	-	Rollier C (2020)	This work was funded by a gra	
RR15459	National Center for Research Resources	-	-	-	-	Rollier C (2020)	This work was funded by a gra	
P51 RR000167	National Centre for Research Resources	-	-	-	-	Spencer et al (2014)	This work has been funded by	
RR020141	National Centre for Research Resources	-	-	-	-	Spencer et al (2014)	This work has been funded by	
RR15459	National Centre for Research Resources	-	-	-	-	Spencer et al (2014)	This work has been funded by	
-	National Health Service Blood and Trans	-	-	-	-	Ewer et al (2016)	Supported by the Wellcome T	
-	National Institute of Health and Research	-	-	-	-	Tiono (2018)	This work was supported by a	
-	National Institute of Allergy and Infectio	-	-	-	-	Sheehy et al (2012 - 2)	This work was supported by tl	
-	National Institute for Health and Resean	-	-	-	-	Barnes et al (2012)	European Union (Framework'	
-	National Institute for Health Research	-	-	-	-	Bowyer G (2020)	The Oxford clinical trial was s	
-	National Institute for Health Research	-	-	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup	
-	National Institute for Health Research	-	-	-	-	Folegatti P.M.(2020)	UK Department of Health and	
-	National Institute for Health Research	Rollier C	-	-	-	Rollier C (2020)	This work was funded by a gra	
-	National Institute for Health Research	Hill A.V.S.	-	-	-	Rollier C (2020)	This work was funded by a gra	
-	National Institute for Health Research	-	-	-	-	van Doremalen N (2020)	This work was supported by tl	
-	National Institute for Health Research	-	-	-	-	van Doremalen N (2020)	This work was supported by tl	
-	National Institute of Allergy and Infectio	-	-	-	-	Sheehy et al (2012)	This work was supported by	
HHSN272201400008C	National Institute of Allergy and Infectio	Icahn School Of Medicine At	09/01/2014	\$78,100,000	0.72	£ 56,232,000.00	S Graham (2020)	Developmentof SARS-CoV-2 r
-	National Institute of Allergy and Infectio	-	-	-	-	Biswas et al (2014)	This work was supported by tl	
-	National Institute of Allergy and Infectious Diseases	-	-	-	-	Sheehy et al (2011)	This work was supported by tl	
-	National Institute of Allergy and Infectio	-	-	-	-	Tapia et al (2016)	This study was funded by a W	
-	National Institute of Allergy and Infectio	EMMES Corporation	-	-	-	Tapia et al (2016)	This study was funded by a W	
HHSN261200800001E	National Institute of Allergy and Infectio	Leidos Biomedical Research	-	-	-	Tapia et al (2016)	This study was funded by a W	
R44AI058375	National Institute of Allergy and Infectio	-	-	-	-	Tapia et al (2016)	This study was funded by a W	
-	National Institute of Allergy and Infectious Diseases	-	-	-	-	Longley et al (2017)	Funding for manufacture and	
-	National Institute of Allergy and Infectious Diseases	-	-	-	-	Draper et al (2011)	SB was funded by MalParTrai	

	National Institute of Allergy and Infectio	-	-					Payne et al (2017)	This work was supported by fi	
	National Institute of Allergy and Infectio	-	-					van Doremalen N (2019)	This work was supported by ti	
	National Institute of Allergy and Infectio	-	-					van Doremalen N (2020)	This work was supported by ti	
	National Institute of Allergy and Infectio	-	-					van Doremalen N (2020)	This work was supported by ti	
HHSN272201400008C	National Institute of Allergy and Infectio	-	-					van Doremalen N (2020)	This work was supported by ti	
	National Institute of Health	-	-					Biswas et al (2014)	This work was supported by ti	
	National Institute of Health	-	-					Folegatti P.M. (2019)	This research was funded by f	
	National Institute of Health	Hill A.V.S	-					Gola (2018)	A.G. is funded by the Wellcon	
	National Institute of Health	-	-					Reyes-Sandoval (2010)	Work in the Oxford malaria ve	
	National Institute of Health	-	-					Rollier C (2020)	This work was funded by a gr	
	National Institute of Health	-	-					Sheehy et al (2012)	This work was supported by	
	National Institute of Health	-	-					Sheehy et al (2012 - 2)	This work was supported by ti	
HHSN272201400008C	National Institute of Health	-	-					Bliss (2020)	This research project was sup	
	National Institute of Health	-	-					Draper et al (2011)	SB was funded by MalParTrai	
HILL05GCGHO	National Institute of Health	-	-					Spencer et al (2014)	This work has been funded by	
	National Institute of Health and Researc	-	-					Bowyer (2018)	The clinical trial was supporte	
	National Institute of Health and Researc	-	-					Coughlan L (2018)	Medical Research Council UK,	
	National Institute of Health and Researc	-	-					Venkatraman N (2019)	This work was supported	
	National Institute of Health and Researc	-	-					Bliss (2018)	This study was funded by the	
	National Institutes of Allergy and Infecti-	-	-					Forbes et al (2012)	This work was funded by the \	
1ZIAAI001179-01	National Institutes of Health	<u>MUNSTER, VINCENT</u>	2013	\$877,861		0.72	£	632,059.92	van Doremalen N (2020)	This work was supported by ti
	National Institutes of Health	-	-					Forbes et al (2012)	This work was funded by the \	
	National Institutes of Health	-	-					Sheehy et al (2011)	This work was supported by ti	
	National Institutes of Health, National In-	-	-					Hodgson et al (2014)	This work was supported by ti	
	NDM	Biswas S	-					Biswas et al (2014)	This work was supported by ti	
26-6.	NEKKEN	Iyori M	2014	-				Yoshida Kiyori (2018)	This work was supported, in p	
27-5.	NEKKEN	Iyori M	2015	-				Yoshida Kiyori (2018)	This work was supported, in p	
EC FP7	NEWTBVAC	-	-					Betts et al (2012)	Funding was provided by NEW	
	1041802 NHMRC	McCarthy JS	-					Payne (2017)	This work was supported by a	
	10418020 NHMRC	McCarthy JS	-					Payne et al (2017)	This work was supported by fi	
5T32AI007647-17	NIAID	PALESE, PETER	04-May-16	\$523,884		0.72	£	377,196.48	Asthagiri Arunkumar (2019)	The study was fundedby an M
1R03AI142046-01	NIAID	<u>ALBRECHT, RANDY A.</u>	01-Dec-18	\$84,750		0.72	£	61,020.00	McHanon M (2019)	The study was fundedby an M
	NIAID	Gola A	-					Gola (2018)	A.G. is funded by the Wellcon	
	NIAID	Uderhardt S	-					Gola (2018)	A.G. is funded by the Wellcon	
	NIAID	Germain RN	-					Gola (2018)	A.G. is funded by the Wellcon	
	NIAID	-	-					Munster (2017)	This work is published withthe	
AI109946	NIAID	-	-					McHanon M (2019)	The study was fundedby an M	
HHSN272201400008C	NIAID	-	-					Asthagiri Arunkumar (2019)	The study was fundedby an M	
HHSN272201400008C	NIAID	-	-					McHanon M (2019)	The study was fundedby an M	
1U19AI082630-01	NIH	<u>CHUNG, RAYMOND T</u>	07-Jun-09	\$3,086,377		0.72	£	2,222,191.44	Barnes et al (2012)	European Union (Framework'
2U19AI082630-06	NIH	<u>CHUNG, RAYMOND T</u>	30-May-14	\$2,351,111		0.72	£	1,692,799.92	Kelly et al (2016)	Supported by a Medical Resez
	NIH	-	-					Munster (2017)	This work is published withthe	
2U19AI082630-06	NIH	Klenerman P	-					Kelly et al (2016)	Supported by a Medical Resez	
2U19AI082630-06	NIH	Kelly C	-					Swadling (2016)	Supported by the Medical Res	
2U19AI082630-06	NIH	Klenerman P	-					Swadling (2016)	Supported by the Medical Res	
HILL05GCGHO	NIH	-	-					Dicks et al (2015 - 2)	This work has been funded by	
	NIH foundation	-	-					Dicks et al (2012)	This work has been funded by	
	NIHR	-	-					Mensah (2017)	This work was supported by a	
	NIHR	-	-					Payne (2017)	This work was supported by a	
	NIHR	Hill AVS	-					Walker et al (2015)	Andrew S. Walker, José Loure	
	NIHR	Hill AVS	-					Ewer et al (2013)	The study was funded by gran	
	NIHR	-	-					Reyes-Sandoval et al (2010)	We thank the Jenner Institu	
	NIHR (Oxford Biomedical Research Centi-	-	-					O'Hara et al (2012)	Financial support. This work v	

A91301 Adult Vaccine	NIHR (through Oxford Biomedical Resea	-	-	Sheehy et al (2011)	This work was supported by ti
-	NIHR Oxford Biomedical Research Centri	-	-	Antrobus et al (2014)	The study was funded by gran
-	NIHR Oxford Biomedical Research Centri	-	-	Cottingham et al (2012)	This work was supported by ti
-	NIHR Oxford Biomedical Research Centri	-	-	Elias et al (2013)	This work was supported by ti
-	NIHR Oxford Biomedical Research Centri Barnes E	-	-	Swadling et al (2014)	Funding:Supported by the Mei
-	NIHR Oxford Biomedical Research Centri	-	-	Ewer et al (2013)	The study was funded by gran
084113/Z/07/Z	NIHR Oxford Biomedical Research Centri	-	-	Biswas et al (2014)	This work was supported by ti
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centri	-	-	de Barra et al (2014)	The study was funded by a gr
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centri	-	-	Kimani et al (2014)	This work was supported by
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centri	-	-	Ogwang et al (2013)	This work was performed by t
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centri	-	-	Sheehy et al (2012 - 2)	This work was supported by ti
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centri	-	-	Sheehy et al (2012)	This work was supported by
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centri	-	-	Hodgson et al (2014)	This work was supported by ti
A91301,Adult Vaccine	NIHR Oxford Biomedical Research Centri	-	-	Hodgson et al (2015)	This work was supported by ti
-	NIHR Oxford BRC	-	-	Capuccini et al (2017)	This work was supported by C
-	NIHR Oxford BRC	-	-	Ewer et al (2016)	Supported by the Wellcome T
-	NIHR Oxford BRC	-	-	Longley et al (2017)	Funding for manufacture and
-	NIHR Oxford BRC	-	-	Payne et al (2017)	This work was supported by ft
-	NIHR Oxford BRC	-	-	Rampling et al (2016)	This work was supported by ti
-	NIHR Oxford BRC Kelly C	-	-	Swadling (2016)	Supported by the Medical Res
-	NIHR Oxford BRC Klenerman P	-	-	Swadling (2016)	Supported by the Medical Res
-	NIHR Oxford BRC Barnes E	-	-	Swadling (2016)	Supported by the Medical Res
91301 Adult Vaccine	NIHR Oxford BRC	-	-	Afolabi et al (2016)	Trials Partnership (EDCTP) anc
58-5348-2-117F	Norman Borlaug Commemorative Resea	-	-	Svitek (2018)	This work was funded by the f
-	Nuffield Department of Medicine	Reyes-Sandoval A	-	Reyes-Sandoval et al (2010)	We thank the Jenner Institu
-	Nuffield Department of Medicine	Longley RJ	-	Longley et al (2015)	This work has been funded by
-	Nuffield Department of Medicine	Longley RJ	-	Longley et al (2017)	Funding for manufacture and
-	Oak Foundation	-	-	Stedman (2019)	This study was funded by the
16/107/05	ODA budget	Reyes-Sandoval A, Patel AH	-	Lopez-Camacho (2018)	This report is independent res
-	Ohyama Health Foundation	-	-	Yoshida Klyori (2018)	This work was supported, in p
-	Oxford Biomedical Research Centre	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supj
-	Oxford Biomedical Research Centre	Rollier CS	-	Reyes-Sandoval et al (2010)	We thank the Jenner Institu
-	Oxford Martin Institute	Spencer AJ	-	Longley et al (2017)	Funding for manufacture and
-	Oxford Martin Institute	Hill AVS	-	Salman et al (2017)	The work was funded by a We
-	Oxford Martin School	Reyes-Sandoval A	-	Atcheson (2018)	The work was funded by a We
-	Oxford Martin School	Hill A.V.S	-	Atcheson (2018)	The work was funded by a We
-	Oxford Martin School	Reyes-Sandoval A	-	Bauza et al (2014)	The work was funded by a We
-	Oxford Martin School	-	-	Cottingham et al (2012)	This work was supported by ti
-	Oxford Martin School	Barnes E	-	Kelly et al (2016)	Supported by a Medical Resee
-	Oxford Martin School	Lambe T	-	Lambe et al (2013)	AVL was funded by a fellowsh
-	Oxford Martin School	Spencer AJ	-	Longley et al (2015)	This work has been funded by
-	Oxford Martin School	Reyes-Sandoval A	-	Salman et al (2017)	The work was funded by a We
-	Oxford Martin School	Barnes E	-	Swadling (2016)	Supported by the Medical Res
-	Oxford Martin School	Hill AVS	-	Bauza et al (2014)	The work was funded by a We
-	Oxford Martin School	-	-	Antrobus et al (2014)	The study was funded by gran
-	Oxford Martin School	Spencer AJ	-	Dicks et al (2015)	This work has been funded by
-	Oxford Martin School	Cottingham MG	-	Dicks et al (2015)	This work has been funded by
-	Oxford Martin School	Cottingham MG	-	Dicks et al (2012)	This work has been funded by
-	Oxford Martin Schools	Barnes E	-	Swadling et al (2014)	Funding:Supported by the Mei

-	Oxford NHIRBRC	-	-	-	-	Kelly et al (2016)	Supported by a Medical Resea
-	Oxford NHIRBRC	Barnes E	-	-	-	Kelly et al (2016)	Supported by a Medical Resea
-	Oxford NIHR Biomedical Research Centri-	-	-	-	-	Barnes et al (2012)	European Union (Framework'
-	Oxford NIHR Biomedical Research Centri	Redchenko I	-	-	-	Capuccini et al (2016)	This work was supported by C
-	PATH Malaria Vaccine Initiative	-	-	-	-	Forbes et al (2012)	This work was funded by the \
-	PATH Malaria Vaccine Initiative	-	-	-	-	Hodgson et al (2014)	This work was supported by ti
-	PATH Malaria Vaccine Initiative	-	-	-	-	Rampling T (2018)	This work was funded primari
-	PATH Malaria Vaccine Initiative	-	-	-	-	Sheehy et al (2012)	This work was supported by
-	PATH Malaria Vaccine Initiative	-	-	-	-	Biswas et al (2014)	This work was supported by ti
-	PATH Malaria Vaccine Initiative	-	-	-	-	Rampling et al (2016)	This work was supported by ti
-	PATH Malaria Vaccine Initiative (MVI)	-	-	-	-	Sheehy et al (2011)	This work was supported by ti
-	PATH MalariaVaccine Initiative	-	-	-	-	Hodgson et al (2015)	This work was supported by ti
-	PATH MalariaVaccineInitiative	-	-	-	-	Sheehy et al (2012 - 2)	This work was supported by ti
-	PATH-MVI Malaria Vaccine Initiative	-	-	-	-	Draper et al (2011)	SB was funded by MalParTrai
-	Public Health England	-	-	-	-	Ewer et al (2016)	Supported by the Wellcome T
-	ReiThera (formerly Okairos)	Nicosia A	-	-	-	Mensah et al (2016)	This study was supported by a
-	Rhodes Trust	-	-	-	-	Longley et al (2015)	This work has been funded by
-	Rhodes Trust	Longley RJ	-	-	-	Longley et al (2017)	Funding for manufacture and
-	Rhodes Trust	Llewellyn D	-	-	-	Payne (2017)	This work was supported by a
-	Science Foundation Ireland	-	-	-	-	Carey et al (2013)	This work wassupported by Er
NAP156	Science Foundation Ireland	-	-	-	-	Pearson et al (2015)	This study was funded by Ente
NAP170	Science Foundation Ireland	-	-	-	-	Pearson et al (2015)	This study was funded by Ente
-	Southampton NIHR Wellcome Trust Clini-	-	-	-	-	Sheehy et al (2012)	This work was supported by
-	Southampton NIHR Wellcome Trust Clini-	-	-	-	-	Rampling et al (2016)	This work was supported by ti
AGL2017-82570-R	Spanish Ministry of Science	-	-	-	-	Utrilla-Trigo S (2020)	This work was supported by g
-	Spanish Ministry of Science	Lopez-Gil E	-	-	-	Warimwe et al (2013)	This work was supported by a
AGL2011-22485	Spanish Ministry of Science	Brun AV	-	-	-	Warimwe et al (2013)	This work was supported by a
-	St Catherine's College, Oxford	Biswas S	-	-	-	Biswas et al (2014)	This work was supported by ti
-	Swedish International Development Coop-	-	-	-	-	Afolabi et al (2016)	Trials Partnership (EDCTP) anc
-	Swedish International Development Coop-	-	-	-	-	Mensah (2017)	This work was supported by a
-	Swedish International Development Coop-	-	-	-	-	Mensah et al (2016)	This study was supported by a
-	Swedish International Development Coop-	-	-	-	-	Tiono (2018)	This work was supported by a
-	The Coalition for Epidemic Preparedness-	-	-	-	-	Folegatti P.M.(2020)	UK Department of Health and
-	The Oxford Martin School	Rollier CS	-	-	-	Reyes-Sandoval et al (2010)	We thank the Jenner Institu
EU FP7	Transmolec	-	-	-	-	Goodman et al (2011)	This work was supported prim
EU FP7	Transmolec	-	-	-	-	Goodman et al (2011)	This work was supported prim
-	TRANSVAC	-	-	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supj
-	UK Department for International Develo-	-	-	-	-	Bowyer G (2020)	The Oxford clinical trial was s
-	UK Department for International Develo-	-	-	-	-	Venkatraman N (2019)	This work was supported
Project 16/107/03	UK Department of Health and Social Car-	-	-	-	-	Stedman (2019)	This study was funded by the
16/107/01	UK Department of Health and Social Car-	-	-	-	-	Folegatti P.M.(2020)	UK Department of Health and
EP/R013756/1	UK Engineeringand Physical Sciences Res-	-	-	£6,968,179	£ 6,968,179.00	Fedosyuk S (2019)	This work was supported by N
-	UK Medical Research Council	-	-	-	-	Reyes-Sandoval (2010)	Work in the Oxford malaria ve
-	UK National Institute for Health Researc-	-	-	-	-	Folegatti P.M.(2020)	UK Department of Health and
MC_PC_19055	UK Research and Innovation	<a href="#">Sarah Catherine Gilbert</a>	Apr 20 - Sep 21	£2,174,847	£ 2,174,847.00	Folegatti P.M.(2020)	UK Research and Innovation, t
GR000550	UK Royal Society for Tropical Medicine a	Coughlan L	-	-	-	Bliss (2020)	This research project was sup
972216	UKRI	Reyes-Sandoval A	Oct 16 - Sep 17	£498,870	£ 498,870.00	Lopez-Camacho (2018)	This report is independent res
	UKRI	Alexandar Douglas		£411,388.00	£ 411,388.00	<a href="https://www.ukri.org/research/g">https://www.ukri.org/research/g</a>	This COVID-19 Rapid Respons
	UKRI	Sandy Douglas		£400,000.00	£ 400,000.00	<a href="https://www.ox.ac.uk/news/202">https://www.ox.ac.uk/news/202</a>	Working with Professor Sarah Gilbert
	UKRI	Graham Ogg		£246,000.00	£ 246,000.00	<a href="https://www.ukri.org/rese">https://www.ukri.org/rese</a>	This £246k award is to procur
BBS/E/I/00007037	UKRI Biotechnology and BiologicalScienc	<a href="#">Michael Johnson</a>	Apr 17 - Mar 20	£17,455,044	£ 17,455,044.00	S Graham (2020)	UKRI Biotechnology and Biolc
BBS/E/I/00007039	UKRI Biotechnology and BiologicalScienc	<a href="#">Simon Thomas Carpenter</a>	Apr 17 - Mar 20	£6,662,753	£ 6,662,753.00	S Graham (2020)	UKRI Biotechnology and Biolc
BBS/E/I/00007031	UKRI Biotechnology and BiologicalScienc	<a href="#">Philippa Beard</a>	Apr 17 - Mar 20	£2,965,523	£ 2,965,523.00	S Graham (2020)	UKRI Biotechnology and Biolc
BBS/E/I/00007034	UKRI Biotechnology and BiologicalScienc	<a href="#">Simon Thomas Carpenter</a>	Apr 17 - Mar 20	£2,728,186	£ 2,728,186.00	S Graham (2020)	UKRI Biotechnology and Biolc



EP/R013756/1	UKRI Engineering and Physical Sciences	Tarit K Mukhopadhyay	Apr 18 - Sep 21	£6,968,179	£ 6,968,179.00	S Graham (2020)	This study was supported by U
EP/S025243/1	UKRI Engineering and Physical Sciences	James Henderson Naismith	Nov 18 - May 20	£1,649,512	£ 1,649,512.00	S Graham (2020)	andEPSRC Grant No. EP/S025:
-	University of Oxford	-	-	-	-	Warimwe et al (2016)	This work was conducted with
MRF/TT2015/2150	University of Oxford	Coughlan L	-	-	-	Bliss (2020)	This research project was sup
-	USAID	-	-	-	-	Payne et al (2017)	This work was supported by fi
-	Vaccine Research Center	-	-	-	-	Tapia et al (2016)	This study was funded by a W
-	Vaccitech Ltd	-	-	-	-	Tuthill M. (2020)	European Union Seventh Fran
-	Wellcome Trust	-	-	-	-	Ewer et al (2013)	The study was funded by gran
76438	Wellcome Trust	-	-	-	-	Reyes-Sandoval et al (2010)	We thank the Jenner Institu
206194	Wellcome Trust	-	-	-	-	Payne et al (2017)	This work was supported by fi
-	Wellcome Trust	-	-	-	-	Bowyer G (2020)	The Oxford clinical trial was s
-	Wellcome Trust	AVSH	-	-	-	Capone et al (2010)	This work was supported by tt
-	Wellcome Trust	-	-	-	-	Capone et al (2010)	This work was supported by tt
-	Wellcome Trust	Hill AVS	-	-	-	Capuccini et al (2017)	This work was supported by C
-	Wellcome Trust	-	-	-	-	Reyes-Sandoval (2010)	Work in the Oxford malaria ve
-	Wellcome Trust	Reyes-Sandoval A	-	-	-	Reyes-Sandoval et al (2010)	We thank the Jenner Institu
-	Wellcome Trust	-	-	-	-	Rollier C (2020)	This work was funded by a gr
-	Wellcome Trust	Hill A.V.S.	-	-	-	Rollier C (2020)	This work was funded by a gr
-	Wellcome Trust	-	-	-	-	Venkatraman N (2019)	This work was supported
084113/Z/07/Z	Wellcome Trust	-	-	-	-	Afolabi et al (2016)	Trials Partnership (EDCTP) and
084113/Z/07/Z	Wellcome Trust	-	-	-	-	Longley et al (2017)	Funding for manufacture and
084113/Z/07/Z	Wellcome Trust	-	-	-	-	Payne et al (2017)	This work was supported by fi
095540/Z/11/Z	Wellcome Trust	Hill AVS	-	-	-	Longley et al (2017)	Funding for manufacture and
095540/Z/11/Z	Wellcome Trust	Hill AVS	-	-	-	Salman et al (2017)	The work was funded by a We
097395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A	-	-	-	Alves et al (2017)	The work was funded by a We
097395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A	-	-	-	Salman et al (2017)	The work was funded by a We
097940/Z/11/Z	Wellcome Trust	Hodgson SH	-	-	-	Longley et al (2017)	Funding for manufacture and
106917/Z/15/Z	Wellcome Trust	Draper SJ	-	-	-	Payne et al (2017)	This work was supported by fi
204826/Z/16/Z	Wellcome Trust	Prof Matthew Freeman	07/09/2016	£3,000,000.00	£ 3,000,000.00	Fedosyuk S (2019)	This work was supported by M
106917/Z/15/Z	Wellcome Trust	Prof Simon Draper	01/04/2015	£1,901,424.00	£ 1,901,424.00	Wang (2018)	This work has been supported
095540/Z/11/Z	Wellcome Trust	Hill A.V.S	10/05/2011	£1,372,456.00	£ 1,372,456.00	Atcheson (2018)	The work was funded by a We
95540/Z/11/Z	Wellcome Trust	Prof Adrian Hill	10/05/2011	£1,372,456.00	£ 1,372,456.00	Dicks et al (2015 - 2)	This work has been funded by
97395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A	12/12/2011	£1,081,461.00	£ 1,081,461.00	Bauza et al (2014)	The work was funded by a We
201477/Z/16/Z	Wellcome Trust	Dr Alexander Douglas	18/05/2016	£414,492.00	£ 414,492.00	Wang (2018)	This work has been supported
201477/Z/16/Z	Wellcome Trust	Douglas AD	18/05/2016	£414,492.00	£ 414,492.00	Fedosyuk S (2019)	This work was supported by M
098635/B/12/Z	Wellcome Trust	Warimwe GM	21/06/2012	£253,778.00	£ 253,778.00	Dulal et al (2016)	This study was conducted with
098635/B/12/Z	Wellcome Trust	Warimwe GM	21/06/2012	£253,778.00	£ 253,778.00	Warimwe et al (2013)	This work was supported by a
094449/Z/10/Z	Wellcome Trust	Duncan CJ	31/08/2010	£218,216.00	£ 218,216.00	Sheehy et al (2012)	This work was supported by
089455/Z/09/Z	Wellcome Trust	Douglas AD	29/05/2009	£217,651	£ 217,651.00	Payne et al (2017)	This work was supported by fi
97395/Z/11/A	Wellcome Trust	Reyes-Sandoval A	01/08/2013	£203,200.00	£ 203,200.00	-	-
097940/Z/11/Z	Wellcome Trust	Hodgson SH	29/03/2012	£195,304.00	£ 195,304.00	Kimani et al (2014)	This work was supported by
76438	Wellcome Trust	Prof Adrian Hill	16/09/2008	£84,023.00	£ 84,023.00	Reyes-Sandoval et al (2008)	The work was supported by a
098635/Z/12/Z	Wellcome Trust	Warimwe GM	21/06/2012	£74,551.00	£ 74,551.00	Dulal et al (2016)	This study was conducted with
-	Wellcome Trust	-	-	-	-	Barnes et al (2012)	European Union (Framework'

-	Wellcome Trust	-	-	-	Bliss (2018)	This study was funded by the
-	Wellcome Trust	-	-	-	Boyd et al (2013)	The Biotechnology and Biolog
-	Wellcome Trust	Hill AVS	-	-	Capuccini et al (2016)	This work was supported by C
-	Wellcome Trust	-	-	-	Colloca et al (2012)	This work was supported in p
-	Wellcome Trust	-	-	-	Cottingham et al (2012)	This work was supported by th
-	Wellcome Trust	Hill AVS	-	-	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supj
-	Wellcome Trust	-	-	-	Dicks et al (2012)	This work has been funded by
-	Wellcome Trust	Hill AVS	-	-	Dicks et al (2015 - 2)	This work has been funded by
-	Wellcome Trust	Hill A.V.S	-	-	Draper et al (2010)	This work was funded by the \
-	Wellcome Trust	Hill A.V.S.	-	-	Draper et al (2011)	SB was funded by MalParTrai
-	Wellcome Trust	Gilbert SC	-	-	Draper et al (2011)	SB was funded by MalParTrai
-	Wellcome Trust	-	-	-	Ewer et al (2013)	The study was funded by gran
-	Wellcome Trust	Hill AVS	-	-	Ewer et al (2013)	The study was funded by gran
-	Wellcome Trust	-	-	-	Forbes et al (2012)	This work was funded by the \
-	Wellcome Trust	Hill AVS	-	-	Forbes et al (2012)	This work was funded by the \
-	Wellcome Trust	Hill A.V.S	-	-	Gola (2018)	A.G. is funded by the Wellcon
-	Wellcome Trust	Hill A.V.S	-	-	Gola (2018)	A.G. is funded by the Wellcon
-	Wellcome Trust	Hill A.V.S.	-	-	Goodman et al (2011)	This work was supported prim
-	Wellcome Trust	-	-	-	Halbroth (2018)	BRH received funding from th
-	Wellcome Trust	-	-	-	Kelly et al (2016)	Supported by a Medical Rese
-	Wellcome Trust	Gavin Screaton	-	-	Lopez-Camacho (2018)	This report is independent res
-	Wellcome Trust	-	-	-	Tapia et al (2016)	This study was funded by a W
-	Wellcome Trust	-	-	-	Tapia et al (2016)	This study was funded by a W
-	Wellcome Trust	Hill AVS	-	-	Walker et al (2015)	Andrew S. Walker, José Loure
-	Wellcome Trust	Hill A.V.S	-	-	Halbroth (2018)	BRH received funding from th
-	Wellcome Trust	Hill AVS	-	-	Colloca et al (2012)	This work was supported in p
-	Wellcome Trust	-	-	-	Ewer et al (2016)	Supported by the Wellcome T
-	Wellcome Trust	Kelly C	-	-	Swadling (2016)	Supported by the Medical Res
-	Wellcome Trust	Klenerman P	-	-	Swadling (2016)	Supported by the Medical Res
084113/Z/07/Z	Wellcome Trust	-	-	-	de Barra et al (2014)	The study was funded by a gr
084113/Z/07/Z	Wellcome Trust	-	-	-	Elias et al (2013)	This work was supported by th
084113/Z/07/Z	Wellcome Trust	-	-	-	Hodgson et al (2014)	This work was supported by th
084113/Z/07/Z	Wellcome Trust	Hill AVS	-	-	Hodgson et al (2015)	This work was supported by th
084113/Z/07/Z	Wellcome Trust	-	-	-	Kimani et al (2014)	This work was supported by
084113/Z/07/Z	Wellcome Trust	-	-	-	Sheehy et al (2011)	This work was supported by th
084113/Z/07/Z	Wellcome Trust	-	-	-	Sheehy et al (2012 - 2)	This work was supported by th
084113/Z/07/Z	Wellcome Trust	Prof Adrian Hill	-	-	Sheehy et al (2012)	This work was supported by
091663MA	Wellcome Trust	-	-	-	Colston et al (2016)	This work was supported by V
095540/Z/11/Z	Wellcome Trust	-	-	-	Dicks et al (2015)	This work has been funded by
095540/Z/11/Z	Wellcome Trust	-	-	-	Longley et al (2015)	This work has been funded by
095540/Z/11/Z	Wellcome Trust	-	-	-	Spencer et al (2014)	This work has been funded by
097940/Z/11/Z	Wellcome Trust	Hodgson SH	-	-	de Barra et al (2014)	The study was funded by a gr
097940/Z/11/Z	Wellcome Trust	Hodgson SH	-	-	Hodgson et al (2015)	This work was supported by th
097940/Z/11/Z	Wellcome Trust	Hodgson SH	-	-	Biswas et al (2014)	This work was supported by th
099897/Z/12/A	Wellcome Trust	-	-	-	Colston et al (2016)	This work was supported by V
45488/Z/05	Wellcome Trust	Hill AVS	-	-	de Barra et al (2014)	The study was funded by a gr
45488/Z/05	Wellcome Trust	Hill AVS	-	-	Hodgson et al (2015)	This work was supported by th
45488/Z/05	Wellcome Trust	Hill AVS	-	-	Sheehy et al (2011)	This work was supported by th
45488/Z/05	Wellcome Trust	Hill AVS	-	-	Sheehy et al (2012 - 2)	This work was supported by th
45488/Z/05	Wellcome Trust	Hill AVS	-	-	Sheehy et al (2012)	This work was supported by
RTE10	Wellcome Trust	Duncan CJ	-	-	Sheehy et al (2012 - 2)	This work was supported by th
WT076943MA	Wellcome Trust	McShane H	-	-	Betts et al (2012)	Funding was provided by NEW
WT098051	Wellcome Trust	-	-	-	Bauza et al (2014)	The work was funded by a We
WT098635	Wellcome Trust	Warimwe GM	-	-	Warimwe et al (2016)	This work was conducted with

97395	Wellcome Trust	Reyes-Sandoval A	-	-	-	Betts et al (2012)	Funding was provided by NEW
-	Wellcome Trust	Hill AVS	-	-	-	Dicks et al (2012)	This work has been funded by
-	Wellcome Trust	-	-	-	-	O'Hara et al (2012)	Financial support. This work w
084113/Z/07/Z	Wellcome Trust	-	-	-	-	Ogwang et al (2013)	This work was performed by t
WT 098051	Wellcome Trust	Otto TD	-	-	-	Payne (2017)	This work was supported by a
203077/Z/16/Z	Wellcome Trust	Prof Philip Bejon	30/06/2016	£26,595,243.00	£ 26,595,243.00	Stedman (2019)	This study was funded by the
084113/Z/07/Z	Wellcome Trust	Prof Adrian Hill	07/11/2007	£3,400,000.00	£ 3,400,000.00	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supi
084113/Z/07/Z	Wellcome Trust	Prof Adrian Hill	07/11/2007	£3,400,000.00	£ 3,400,000.00	Payne (2017)	This work was supported by a
106325/Z/14/A	Wellcome Trust	A.V.S Hill	19/12/2014	£2,100,000.00	£ 2,100,000.00	Venkatraman N (2019)	This work was supported
106917/Z/15/Z	Wellcome Trust	Draper SJ	01/04/2015	£1,901,424.00	£ 1,901,424.00	Payne (2017)	This work was supported by a
097395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A	12/12/2011	£1,081,461.00	£ 1,081,461.00	Atcheson (2018)	The work was funded by a We
108734/Z/15/Z	Wellcome Trust	Rawlinson TA	24/06/2015	£271,399.00	£ 271,399.00	Payne (2017)	This work was supported by a
-	Wellcome Trust	A.V.S Hill	-	-	-	Bowyer (2018)	The clinical trial was supporte
-	Wellcome Trust	Gola A	-	-	-	Gola (2018)	A.G. is funded by the Wellcon
-	Wellcome Trust	-	-	-	-	Mensah (2017)	This work was supported by a
-	Wellcome Trust Clinical Research Facilit	-	-	-	-	Barnes et al (2012)	European Union (Framework'